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SUMMARY 
 
Asthma and chronic obstructive pulmonary disease (COPD) are characterized by chronic 
airway inflammation and remodeling. In non-pathological conditions tissue homeostasis is 
maintained by the balance between extracellular matrix (ECM) synthesis and degradation. 
However, this equilibrium is altered in asthma and COPD leading to structural changes such 
as increased ECM deposition. Fibroblasts and airway smooth muscle cells (ASMC) are the 
main source of collagen and glycosaminoglycans (GAGs) and transforming growth factor-β1 
(TGF-β1) is the most potent ECM stimulator in vitro. In turn, the ECM influences cell 
proliferation, migration, differentiation, and secretion of cytokines and growth factors. Thus, 
ECM deposition may perpetuate the inflammatory and remodeling processes, contributing to 
progression and severity of diseases. Inhaled corticosteroids and long acting β2-agonists 
(LABA) are the current therapy for asthma and COPD but their effect on airway remodeling 
is not clear. Therefore, the purpose of this thesis was to investigate the effect of 
corticosteroids and LABA on airway inflammation and tissue remodeling using a human cell 
based in vitro model. 
In the present thesis, primary human lung fibroblasts and ASMC were cultured under serum-
free condition to reflect a non-inflammatory environment or with 5% fetal calf serum (FCS) 
and/or TGF-β1 to mimic inflammation. This experimental design allowed us to assess the 
effect of corticosteroids and LABA on total ECM, collagen and GAGs deposition, cell 
proliferation, cytokines release, collagen and ECM mediators mRNA expression, and 
gelatinolytic activity under both non-inflammatory and inflammatory conditions.  
Concerning the effect of corticosteroids and LABA on ECM deposition by fibroblasts, we 
showed that 5% FCS and TGF-β1 increased total ECM and collagen deposition. Under serum-
free condition corticosteroids reduced ECM deposition and the effect was partly mediated by 
the glucocorticoid receptor and collagen de novo synthesis. Interestingly, in the presence of 
5% FCS corticosteroids had the opposite effect. LABA reduced total ECM and collagen 
deposition under both conditions. Combined drugs further decreased ECM deposition under 
serum-free condition whereas they counteracted each other in 5% FCS, independently of 
TGF-β1. Furthermore, we showed that 5% FCS and TGF-β1 increased GAGs secretion and 
deposition. Under serum-free condition corticosteroids inhibited GAGs secretion and 
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deposition whereas LABA alone had no effect but partly reversed the effect of corticosteroids. 
On the contrary, in 5% FCS corticosteroids and LABA increased GAGs deposition. Upon 
TGF-β1 stimulation, similar effects were obtained except in 5% FCS, where both drugs 
decreased the TGF-β1-induced GAGs secretion and deposition. Together, these findings 
indicate that the effect of corticosteroids but not of LABA, on ECM deposition by fibroblasts 
is altered by ongoing inflammation.  
The effects of corticosteroids and LABA on GAGs, matrix metalloproteinases (MMPs) and 
total ECM/collagen deposition by ASMC from healthy, asthma and COPD patients were also 
investigated. First, no difference in GAGs secretion and deposition was observed between 
ASMC from healthy, asthma and COPD patients. Under serum-free condition corticosteroids 
inhibited GAGs secretion and deposition while LABA had no clear effect nor modulated the 
effect of corticosteroids. In 5% FCS corticosteroids decreased GAGs secretion to a greater 
extent than LABA and their combination resulted in the same effect as corticosteroids alone. 
None of the drugs had any effect on GAGs deposition. Second, we assessed the effect of the 
drugs on ASMC-derived MMPs. In ASMC only proMMP-2 gelatinolytic activity was 
detected, which was decreased in asthma and COPD patients compared to healthy controls. 
However, corticosteroids and/or LABA had no effect on proMMP-2 activity. Lastly, we 
demonstrated that corticosteroids and LABA generated similar effects on total ECM and 
collagen deposition by ASMC from healthy subjects as observed with fibroblasts. 
In conclusion, our novel findings suggest that the action of corticosteroids and LABA on 
ECM deposition differs under non-inflammatory and inflammatory conditions in lung 
fibroblasts and ASMC. In the presence of acute inflammation with vessel leakage, increased 
ECM deposition may be regarded as an attempt of stromal cells to block further serum and 
cells infiltration into the tissue and this effect would be supported by corticosteroids. The 
addition of LABA would counteract the corticosteroid-induced ECM deposition and therefore 
their combination with corticosteroids may depend on the inflammatory status of the patient. 
Thus, when airway inflammation is resolved, combination therapy may beneficially reduce 
pathological tissue remodeling. Thus, our findings might have implications for the short- and 
long-term treatment strategies in regard to airway remodeling in asthma and COPD. 
CHAPTER 1 
INTRODUCTION 
 
Asthma and chronic obstructive pulmonary disease (COPD) are among the world’s most 
prevalent diseases. Both are characterized by chronic inflammation and structural alterations 
resulting in lung functional abnormalities, with partly reversible airflow limitation in asthma 
and irreversible airway obstruction in COPD. In the following, asthma and COPD will be 
defined and their epidemiology, risk factors and pathogenesis will be described. Then, the 
characteristics of airway remodeling will be outlined. Finally, the actual therapy for asthma 
and COPD and its effect on airway remodeling will be discussed.  
1.1. ASTHMA  
Definition 
Asthma is a complex airway disorder resulting in airflow limitation that presents different 
clinical phenotypes in adults and children. Exacerbations of asthma (attacks or worsening of 
asthma symptoms and lung function) can be fatal in absence of effective treatment. The 
Global Initiative for Asthma defined asthma as:  
“a chronic inflammatory disorder of the airways in which many cells and 
elements play a role. The chronic inflammation causes an associated increase 
in airway hyperresponsiveness that leads to recurrent episodes of wheezing, 
breathlessness, chest tightness and coughing, particularly at night or in the 
early morning. These episodes are usually associated with widespread but 
variable airflow obstruction that is often reversible either spontaneously or 
with treatment” [1].  
Asthma is characterized by airway hyperresponsiveness, reversible airflow obstruction, 
chronic airway inflammation and tissue remodeling. Airway hyperresponsiveness is defined 
as an exaggerated bronchoconstriction in response to a wide variety of stimuli. Airflow 
limitation can be caused by several factors including acute bronchoconstriction, mucus 
plugging, smooth muscle hypertrophy and hyperplasia. All these manifestations may lead to 
symptoms of wheezing, coughing, mucus secretion, shortness of breath and chest tightness.  
Epidemiology 
Asthma is a major health problem throughout the world. It is estimated that as many as 300 
million people of all ages and ethnic origins suffer from asthma. The World Health 
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Organization (WHO) and the National Institute of Health reported that mortality due to 
asthma has now reached over 180 000 cases annually and that its prevalence is rising by 50% 
every decade, especially among children [1-3]. Furthermore, asthma is a leading cause of 
hospitalization in young children in industrialized countries. Asthma severity and morbidity, 
which refers to the impact of the disease on a person’s quality of life (medication, 
hospitalization, absence from work/school and disability) are also increasing [3]. Therefore, 
asthma is a substantial human and economic burden for the society [4].  
Risk factors 
Host factors 
Asthma usually develops in childhood and genetic and environmental factors contribute to its 
progression. Individuals with a family history of atopy, which is defined as the production of 
abnormal amounts of immunoglobulin E (IgE) antibodies in response to common 
environmental allergens, have a higher risk of developing airway responsiveness and asthma. 
Indeed, atopy is causing more than 50% of all asthma cases [5, 6]. Gender, age and race may 
also contribute to prevalence of asthma. Over the last years, gene profiling from asthmatic 
tissues have provided evidences that genes related to apoptosis, arginine metabolism, tissue 
repair, proteases and pro-inflammatory cytokines may be involved in the pathogenesis of the 
disease [7-15] but no specific gene has been identified to be responsible for the disease.  
Environmental factors 
In addition, the likelihood that asthma will develop in predisposed individuals depends on 
environmental factors such as exposure to allergens (house dust mites, pets, cockroaches, 
grass pollen), cigarette smoke, occupational sensitizers (chemical irritants, fumes) and air 
pollution [16, 17]. In addition, cold air, physical exercise, respiratory tract infections and 
strong emotional stress can trigger asthma exacerbations [1]. 
Pathogenesis 
Airway inflammation 
Airway inflammation in asthma is a multicellular process that involves mast cells, TH2 
lymphocytes and eosinophilic infiltration and their mediator release (Fig. 1.1). The 
inflammatory changes can occur throughout the central and peripheral airways and often vary 
with the severity of the disease [18, 19]. 
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Figure 1.1. Asthmatic allergic inflammation following allergen exposure in sensitized individuals. Inhaled 
antigen activates mast cells and TH2 cells in the airways and results in release of mediators (histamine, 
leukotrienes) along with cytokines (IL-4, IL-5, GM-CSF). These various compounds induce localized 
inflammatory cell influx and activation through upregulation of chemokines and adhesion molecules. Figure by 
Busse and Lemanske with permission from N Engl J Med [20]. 
 
Mast cell 
Asthma is typically triggered by allergens and the classical inflammatory response takes place 
in two distinct phases: an early-phase reaction followed by a late-reaction [21]. The early-
phase reaction of a sensitized individual initiates when IgE antibodies bind with high-affinity 
to their receptors FcεRI on mast cells, leading to their activation. Mast cells respond within 
minutes, they degranulate and release their preformed mediators such as histamine and 
tryptase and newly synthesized products such as prostaglandin D2 and leukotriene C4. These 
mediators induce constriction of the airways and may also alter vascular permeability. This 
early-phase reaction usually resolves within an hour. Four to six hours later, a prolonged late-
phase reaction may develop as a result of cytokines and chemokines secreted by resident and 
recruited inflammatory cells. Mast cells further contribute to this chronic inflammation 
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through the release of pro-inflammatory cytokines including interleukin (IL)-4, IL-5, IL-13, 
tumor necrosis factor-α (TNF-α), and granulocyte/macrophage-colony stimulating factor 
(GM-CSF) which regulate the development of eosinophilic inflammation [21, 22].    
TH2 lymphocyte  
As reviewed by Busse and Lemanske, the “TH2 hypothesis” proposes that an imbalance in 
favor of TH2 cells leads to allergic inflammation in asthma [20]. Indeed, the allergic 
inflammatory response in asthma is largely regulated by TH2 cytokines including IL-4, IL-5 
and IL-13 [23-25]. Briefly, IL-5 regulates differentiation, activation and survival of 
eosinophils and stimulates their release into the circulation [26, 27]. IL-4 controls TH2 cell 
differentiation and expression of vascular cell adhesion molecule-1 (VCAM-1) on endothelial 
cells [28]. IL-13 shares many functions with IL-4 but it is also involved in airway 
hyperresponsiveness, airway fibrosis, epithelial damage and mucus production [29, 30]. 
Interestingly, genes for these cytokines cluster in a region constantly associated with asthma 
linkage studies [31]. In addition, transgenic mice overexpressing these cytokines exhibit 
airway hyperresponsiveness and pathologies similar to the one observed in asthma patients 
[32]. Furthermore, the transcription factor GATA-3, which is a key regulator of TH2 response, 
is overexpressed in asthmatic airways [33, 34], whereas the transcription factor T-bet, which 
controls TH1 differentiation, is undetectable [35, 36]. Thus, in asthmatics TH2 cytokines 
increase the magnitude and/or prolong the inflammatory response.  
Eosinophil  
Despite ongoing controversy, evidences indicate a major role for eosinophils in the 
pathogenesis of asthma [37, 38]. In the bone marrow, IL-5 regulates the terminal 
differentiation of eosinophils, their activation and their release into the circulation. 
Eosinophils migrate to the inflamed area by rolling, through interactions with selectins and 
adhere to the endothelium via binding of integrins to adhesion molecules [39]. Under the 
influence of various cytokines and chemokines, eosinophils migrate through the extracellular 
matrix (ECM) of the airways and their survival is prolonged by IL-5 and GM-CSF [40, 41]. 
Activated eosinophils release pro-inflammatory cytokines such as IL-2, IL-4, IL-5, IL-13 and 
transforming growth factor-β1 (TGF-β1), chemokines (RANTES, eotaxin), LTC4 and 
cytotoxic granule proteins. All these mediators orchestrate vascular permeability, mucus 
secretion, fibrosis, smooth muscle contraction, tissue damage and inflammation [42]. 
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Neutrophil  
Prominent neutrophil infiltration preferentially occurs in severe asthma, which cases are 
usually less sensitive to corticosteroids treatment. Indeed, neutrophil levels are elevated in 
sputum from exacerbated asthmatics, in bronchial washes from patients with status 
asthmaticus and in autopsy samples from patients who died of asthma [43-46]. 
Airway remodeling 
Structural changes of the airway wall, collectively referred as airway remodeling, may result 
from chronic inflammation or chronic tissue injury. Briefly, tissue remodeling includes 
thickening of the airway wall, damages to the epithelium, airway smooth muscle cell (ASMC) 
hypertrophy/hyperplasia, angiogenesis and ECM deposition [47] and will be detailed later.  
Treatment 
There is no curative treatment for asthma. The basis of therapy consists of long-term 
suppression of airway inflammation with corticosteroids plus relief of airway constriction 
with bronchodilators such as long-acting β2-agonists (LABA) [48]. Leukotriene receptor 
antagonists, which act to suppress inflammation and are also bronchodilators, have been 
successfully introduced for the treatment of asthma some years ago [49]. However, their 
efficacy is inferior to the combination of corticosteroids and LABA. Potential drug targets are 
under investigation for asthma, focusing on the inhibition of TH2 cytokine activity [50, 51]. 
For example, a monoclonal antibody against IL-5 has been shown to reduce circulating 
eosinophils after allergen challenge in subjects with asthma but had no effect on 
bronchoconstriction [52]. These findings suggest that eosinophils might rather be a surrogate 
marker than a pathophysiologically important cell type in asthma. A recombinant human IL-4 
receptor showed efficacy in preventing decline in lung function and symptoms in patients 
with moderate and persistent asthma [53]. A recombinant humanized monoclonal IgE 
antibody showed positive results by attenuating allergic responses and improving asthma 
symptoms and exacerbations, and is now approved for treatment of patients not properly 
controlled with corticosteroids and LABA [54, 55]. In summary, inhaled corticosteroids and 
LABA remain the cornerstone therapy for asthma.  
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1.2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
Definition 
COPD is a preventable disease characterized by slowly progressive development of airflow 
limitation that is poorly reversible by treatment. The Global Initiative for Chronic Obstructive 
Lung Diseases defined COPD as: 
“a disease state characterized by airflow limitation that is not fully 
reversible. The airflow limitation is usually both progressive and associated 
with an abnormal inflammatory response of the lungs to noxious particles or 
gases” [56].   
COPD is a complex chronic inflammatory state that encompasses 1) chronic bronchitis, 
defined by chronic cough, mucus secretion and obstruction of the small airways; 2) 
obstructive bronchiolitis, defined by small airway obstruction with inflammation and fibrosis; 
and at the end stage 3) emphysema, with enlargement of airspaces and loss of elasticity as a 
result of permanent destruction of the alveolar walls in the lung parenchyma [57]. Most 
COPD patients have a combination of these three pathological mechanisms assumed to be all 
induced by smoking but may differ in their proportion. The characteristic symptoms of COPD 
are cough, wheeze, sputum production, breathlessness upon physical efforts and frequent 
episodes of bronchitis or chest infections. COPD develops slowly over many years and is 
usually diagnosed when the disease is already advanced.  
Epidemiology  
COPD is not accurately diagnosed and treated, resulting in underestimation of the actual 
burden of the disease [58]. Based on data from the WHO in 2004, COPD is ranked as the 4th 
leading cause of death worldwide and as the 13th cause of morbidity. In addition, the 
worldwide prevalence of COPD in 2002 was estimated to be 11.6/1000 in men and 8.77/1000 
in women [59]. By 2020, COPD is predicted to become the 3rd leading cause of death and the 
5th commonest cause of morbidity [60-62]. COPD patients have to be treated for years, 
resulting in substantial economic and social burdens. 
Risk factors 
Host factors 
To date, the only proven genetic risk factor for COPD is the severe hereditary deficiency of 
α1-antitrypsin, a major circulating inhibitor of serine proteases protecting tissues against 
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degradation, which affects about 1 in 2000-5000 individuals and accounts for 1 to 3% of 
COPD cases [63]. Beside α1-antitrypsin, genes involved in proteolysis/antiproteolysis, 
xenobiotic metabolism, antioxidation, mucociliary clearance and inflammation may 
potentially be involved in the pathogenesis of COPD [64-69]. Impaired lung growth in 
premature babies, diets deficient in antioxidants and gender may also contribute to the 
susceptibility of developing COPD [67, 70]. 
Environmental factors 
COPD is likely caused by an interaction between genetic factors and environmental 
exposures. In industrialized countries, cigarette smoking is by far the most important risk 
factor for COPD, accounting for approximately 90% of all cases [71-73]. However, there is a 
great variability in lung function among smokers as only 10 to 20% develop clinically 
relevant symptoms of COPD. Other environmental risk factors for COPD include 
occupational dusts and chemicals (vapours, irritants, fumes), indoor/outdoor air pollution and 
bacterial/viral infections [56, 74].  
Pathogenesis 
COPD comprises pathological changes in the central and peripheral airways, lung 
parenchyma and pulmonary vasculature. These changes include progressive destruction and 
aberrant repair of the lung parenchyma and result from chronic airway inflammation, 
proteases/antiproteases imbalance and oxidative stress (Fig. 1.2). 
Airway inflammation 
Both COPD and asthma involve chronic airway inflammation but with distinct characteristics 
[75]. In COPD, pulmonary inflammation predominantly affects the peripheral airways and 
lung parenchyma and correlates with the severity of airflow limitation [76-81]. The ongoing 
inflammation is associated with increased number of macrophages, neutrophils and CD8+ T 
lymphocytes, which all release multiple mediators such as pro-inflammatory cytokines, 
leukotrienes, chemokines, growth factors and proteases [82-87]. Oxidants derived from 
cigarette smoke and inflammatory cells activate macrophages to release pro-inflammatory 
mediators including TNF-α, IL-8 and LTB4, mostly regulated by the transcription factor 
nuclear factor-κB (NF-κB) [88-90]. These mediators enhance neutrophil recruitment, 
orchestrate tissue destruction and chronic inflammation, and perpetuate bronchoconstriction, 
airway remodeling and mucus hypersecretion [79, 91, 92]. Interestingly, smoking cessation 
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does not resolve airway inflammation, suggesting that there might be mechanisms that 
maintain the chronicity of inflammation once it is established [93]. 
 
Figure 1.2. Complexity of the inflammatory, proteases/antiproteases and oxidative stress response in 
COPD. Reactive oxygen species resulting from cigarette smoke and inflammatory cells promote inactivation of 
histone deacetylase (HDAC), leading to transcription of NF-κB-mediated cytokines, neutrophil chemokines 
(TNF-α, IL-8) and proteases. These factors further recruit and activate neutrophils to the lung. Through their 
mediator release, CD8+ T cells also activate macrophages. Besides digesting ECM, matrix metalloproteinases 
(MMPs) and neutrophil elastase degrade their inhibitors, the tissue inhibitor of metalloproteinases (TIMPs) and 
α1-antitrypsin, enhancing their matrix-degrading capacities leading to emphysema. Figure by Shapiro with 
permission from N Engl J Med [92]. 
 
Proteases/antiproteases imbalance 
In COPD, there is a loss of elasticity and destruction of the lung parenchyma, indicating that 
elastin and collagen are major targets of serine, cysteine proteases and MMPs [94, 95]. 
Neutrophils secrete the serine proteases neutrophil elastase and cathepsins, MMP-8 and 
MMP-9, all contributing to ECM destruction. Alveolar macrophages also secrete MMP-2, 
MMP-9, MMP-12 and cathepsins [86, 96-98]. The levels of these proteases are elevated in 
bronchoalveolar lavage fluid (BALF) and sputum of COPD patients [99-101]. Under 
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physiological tissue repair, proteases are in balance with their specific inhibitors, including 
α1-antitrypsin and TIMPs, but this balance is altered in COPD [95, 102].  
Oxidative stress 
Each puff of cigarette smoke generates 1015 to 1017 free radicals. These reactive oxygen 
species and the one produced by inflammatory cells decrease the antiprotease activity and 
activate transcription of neutrophil chemokines [103-105]. These cellular damages may 
amplify the inflammatory response, mucus secretion, bronchoconstriction and exacerbations 
in COPD patients [57, 106, 107]. 
Treatment 
At present, no therapies are effective at reversing progression of COPD but they increase 
physical capacity and reduce symptoms, number and severity of exacerbations. Smoking 
cessation at all stages of COPD is the most important therapeutic intervention to reduce 
progression of the disease [108]. Beside smoking cessation, COPD guidelines recommend the 
use of bronchodilators, anticholinergics or LABA, as the first line of treatment for 
symptomatic COPD patients [109-111]. In addition, high-dose of inhaled corticosteroids have 
been shown to reduce the frequency and/or severity of exacerbations in patients with severe 
COPD but were ineffective at reducing the progression of the disease [112-116]. The 
inflammation in COPD is largely resistant to the anti-inflammatory effects of corticosteroids 
[117-119]. This resistance seems to be caused by reduced activity of the nuclear enzyme 
HDAC-2 required for corticosteroids to switch off inflammatory genes [120-122]. 
Nevertheless, inhaled corticosteroids are recommended as an add-on therapy to 
anticholinergics and LABA in patients with severe COPD and frequent exacerbations, leading 
to improvement of lung function together with a marked reduction in symptoms [123-126].   
 
1.3. AIRWAY REMODELING 
Airway remodeling leads to changes in structures of the airways and connective tissue 
through different dynamic processes such as differentiation, migration and proliferation of 
structural cells. Although the exact relationship between airway remodeling and the 
pathogenesis of asthma and COPD remains unclear, remodeling definitely occurs in both 
diseases with differences in the structures, anatomic sites and cell types involved [127-130]. 
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Airway remodeling in asthma 
Characteristics 
Airway remodeling in asthma seems to occur in childhood with pathological structural 
changes appearing even before the development of symptoms [131-134]. As shown in Fig. 
1.3, epithelium damages, thickening of the reticular basement membrane, subepithelial 
fibrosis, ASMC hyperplasia and hypertrophy and increased vascularity are the major features 
of remodeling in asthma. Furthermore, these pathological changes have been associated with 
the duration and severity of the disease [135-140]. 
 A. Non-asthma B. Mild-moderate asthma C. Severe asthma 
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Figure 1.3. Structural changes in airways of asthma patients. Histology of airways of (A) an individual who 
died of causes unrelated to asthma, (B) a patient with mild-moderate asthma and (C) a patient with severe asthma 
who died of status asthmaticus. (1) A marked thickening of the basement membrane and (2) increased smooth 
muscle mass are apparent in the asthmatic airways. Figure by Borger et al. [141]. 
 
Epithelial damage 
In asthma, the bronchial epithelium is highly abnormal with epithelial cell desquamation also 
termed “epithelial shedding”, epithelial metaplasia, goblet cell hyperplasia and increased 
mucus secretion [142-144]. The number of goblet cells in asthma correlates with the 
expression and activation of mucins, thereby contributing to mucus hypersecretion, lumenal 
plugging and asthma severity [145-149]. 
Reticular basement membrane thickening 
The “true” basement membrane consists of the lamina rara and lamina densa and is not altered 
in asthma patients. However, the lamina reticularis localized just below the basement 
membrane is 10 to 15 µm in depth, which is typically twice the thickness found in non-
diseased bronchi [150]. Indeed, this subepithelial fibrosis results from increased deposition of 
collagen (types I, III, V), fibronectin, tenascin and glycosaminoglycans (GAGs) [151-156] 
1
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and correlates with the number of myofibroblasts below the reticular basement membrane 
[157, 158]. Furthermore, the increase in reticular basement membrane parallels the whole 
airway wall thickening in patients with asthma [159, 160]. 
ASMC hypertrophy and hyperplasia 
Hyperplasia or hypertrophy of ASMC is another hallmark of the submucosa in asthma 
patients and plays a critical role in the development of airway narrowing [161-163]. In vitro, 
ASMC from asthma patients have a higher proliferation rate compared to non-asthmatics 
[164]. In addition, they produce more growth factors and ECM proteins, suggesting an 
autocrine regulation of their own proliferation [165-167]. This increased proliferation in 
asthmatic ASMC has been linked to a translational defect in the transcription factor 
CCAAT/enhancer binding protein α (C/EBPα), an inhibitor of ASMC proliferation [168]. 
Angiogenesis and increased vascularity  
Increased airway vascularity in mild-to-severe asthmatics has been shown to contribute to 
airway wall thickening and oedema [169-172]. This elevated number of vessels has been 
associated with overexpression of vascular endothelial growth factor (VEGF) and 
angiogenesis [173-178]. Furthermore, overexpression of VEGF in the airway wall seems to 
correlate with basement membrane thickening in asthma patients [179].   
Pathogenesis 
The precise sequence of events during the development of airway remodeling in asthma 
remains poorly understood. However, inflammatory, epithelial and structural cells are actively 
involved via secretion of cytokines and growth factors. In turn, these mediators may affect the 
phenotype, proliferation and secretory response of these same cells. To date, three hypotheses 
have been suggested to trigger remodeling in asthma: chronic inflammation, defect in 
epithelial repair and epithelial/mesenchymal communication and mechanical stress.  
Repeated episodes of allergic inflammation  
The most accepted hypothesis on the origin of remodeling in asthma is that structural changes 
are secondary to an underlying chronic inflammation. Indeed, repeated episodes of acute 
allergic inflammation constantly activate mast cells, TH2 lymphocytes and eosinophils, 
leading to increased secretion of mediators. In vitro, various pro-inflammatory cytokines and 
growth factors, including IL-4, IL-13, TNF-α and TGF-β1, have been shown to increase 
collagen type I, III, tenascin and GAGs synthesis by lung fibroblasts [180-184]. Moreover, 
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the serine protease tryptase released by degranulating mast cells has been reported to 
stimulate fibroblasts and ASMC proliferation as well as type I collagen synthesis [185]. In 
addition, eosinophilic inflammation has been linked to thickening of the reticular basement 
membrane [186-188]. Therefore, chronic inflammation constantly activates inflammatory 
cells, which produce pro-inflammatory cytokines and growth factors, promoting 
mesenchymal cells differentiation and increased ECM synthesis.  
Defective epithelial repair and epithelial-mesenchymal communication  
Airway remodeling in asthma may also result from a defect in epithelial repair with 
reactivation of epithelial-mesenchymal trophic unit [189, 190]. This describes the interactions 
between the bronchial epithelium and the mesenchymal cells immediately underneath and is 
essential for lung branching and morphogenesis. Accordingly, repeated epithelial injuries can 
result in prolonged activation of the epithelial-mesenchymal trophic unit and may lead to 
tissue remodeling [191]. In asthma, the epithelial repair is altered and induces the secretion of 
epidermal growth factor, TGF-β1 and fibroblast growth factor, which stimulate differentiation 
and proliferation of myofibroblasts, leading to increased ECM deposition [143, 192-195].  
Mechanical stress  
Airway obstruction produces constant folding of the airway wall. In response to such 
mechanical stress, epithelial cells adapt their phenotype and signal to nearby mesenchymal 
cells in order to activate tissue repair [196]. In vitro, mechanical stress stimulates the secretion 
of growth factors by epithelial cells and differentiation of fibroblasts and ASMC toward a 
pro-fibrotic profile [197-202].  
Clinical consequences 
Because increased airway wall thickening results in reduced airway calibre, airway 
remodeling is a significant contributor to airway narrowing, resulting in persistent airway 
obstruction, hyperresponsiveness and lung function decline [47, 203]. Accordingly, 
thickening of the reticular basement membrane seems to correlate with increased airflow 
limitation and airway hyperresponsiveness [204-207]. Remodeling features may also affect 
mechanical properties of the airway wall resulting in its stiffening [208, 209]. Furthermore, 
increased vascularity and mucus hypersecretion account for considerable swelling of the 
airway wall and obstruction of the lumen [149, 171].  
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Interestingly, depending on the localization and severity of the structural changes, these may 
protect against excessive tissue damages. Fundamentally, thickening of the basement 
membrane may prevent infiltration of inflammatory cells and proteins into the lung 
connective tissue. Indeed, airway wall thickening has been shown in some studies to reduce 
airway reactivity and constriction in asthma patients [150, 210-212]. Such protective effects 
may also be partly explained by the fact that remodeling makes the airway stiffer in order to 
resist dynamic compression during bronchoconstriction. 
Airway remodeling in COPD 
Compared to asthma, less is known about the remodeling process in COPD. The structural 
changes appear later in life in the pathogenesis of the disease, are closely associated with 
smoking and occur primarily to the peripheral airways and parenchyma (Fig. 1.4). 
Structural alterations and functional consequences 
Peripheral airways 
In COPD, the bronchial mucosa is characterized by epithelial cell metaplasia, goblet cell 
hyperplasia, mucous gland enlargement, ASMC hypertrophy and infiltration of inflammatory 
cells into the tissue [78, 127, 130, 213-215]. Pulmonary vascular changes such as thickening 
of the vascular wall, angiogenesis and increased vascularity are also important features of 
remodeling in COPD [171, 216-218]. In contrast to asthma, the thickness of the reticular 
basement membrane is very variable and subjected to controversy in COPD [129]. These 
pathological changes lead to mucus hypersecretion, thickening of the airway wall, airway 
narrowing and airway obstruction that can induce airflow limitation in COPD [81, 219-221]. 
Lung parenchyma 
In addition to collagen, elastin and proteoglycans confer the lung parenchyma its resilience 
necessary to undergo repetitive physiologic stress during breathing and are the major ECM 
components degraded in emphysema [222-224]. Emphysema describes the destruction of 
alveolar walls and parenchyma, histologically represented as holes in the connective tissue, 
which reduce the lung elastic recoil in COPD patients. Seeming controversial, airway and 
alveolar wall fibrosis with increased number of fibroblasts may also be present in parallel 
with parenchymal destruction. Interestingly, tissue repair with increased collagen and elastin 
deposition has also been reported in the alveolar walls of COPD patients [225, 226]. 
Furthermore, it was recently reported that collagen deposition even correlated with lung 
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destruction in human emphysema [227]. Together, emphysema and active tissue repair are 
major pathologic features of COPD and contribute to airflow obstruction and limitation 
responsible for severity of the disease [56]. 
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Figure 1.4. Structural alterations of the peripheral airways and parenchyma in smokers with COPD. (A) 
Presence of goblet cells in the epithelium, thickening of the airway wall with inflammatory cells infiltration and 
increase in smooth muscle mass. (B) Epithelial squamous metaplasia and basement membrane of normal 
thickness. (C) Mucous gland hyperplasia. (D) Inflamed small airway with thickened wall and lumen occlusion 
with inflammatory exudates of mucus and cells. (E) Gross appearance of emphysema. (F) Lung alveoli showing 
microscopic emphysema and subsequent enlargement of alveolar spaces. Figures by Jeffery [127], Hamid et al. 
[228] and Hogg [229]. 
 
Pathogenesis 
In COPD, all these structural changes are mostly attributed to direct injury and inflammation 
from repeated exposures to cigarette smoke, environmental and/or occupational pollutants. In 
peripheral airways, the extent of inflammation is likely to be associated with aberrant repair 
process [127, 230]. The primary mechanism of lung parenchyma destruction is though to be 
an imbalance of endogenous proteases and antiproteases in the lung [95, 231]. Accordingly, 
increased expression and/or activity of proteases have been reported in BALF and lung tissue 
of patients with emphysema [90, 99, 101, 232-236]. Their role in the development of the 
disease was further highlighted by animal studies. For example, instillation of serine proteases 
in rodents induced infiltration of neutrophils in the lung tissue and structural changes 
resembling human emphysema [237-239]. Furthermore, disruption of the alveolar wall and 
airspace enlargement were reported in transgenic mice overexpressing MMP-1 and in TIMP-3 
deficient mice [240, 241]. In addition, cigarette smoke-induced emphysema was prevented in 
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mice deficient for macrophage metalloelastase MMP-12 [96]. These studies show that a 
proteases/antiproteases imbalance in favour of proteolysis leads to lung tissue destruction. 
Thus, chronic inflammation and aberrant repair process seem to be the underlying cause to 
airway wall thickening and parenchymal destruction in COPD. 
Airway remodeling in asthma and COPD: a summary 
In summary, remodeling of the airway wall occurs in both asthma and COPD with differences 
in cellular infiltrates and structural changes as summarized in Table 1.1. Briefly, airway 
inflammation in asthma is characterized by mast cells, eosinophils and CD4+ T lymphocytes 
whereas in COPD, macrophages, neutrophils and CD8+ T lymphocytes are predominantly 
involved. Regarding the structural changes, epithelial shedding and reticular basement 
membrane thickening occur only in asthma, increased smooth muscle occur in large airways 
in asthma and in small airways in COPD, and emphysema is a feature of COPD only.  
Table  1.1. Airway inflammation and remodeling in asthma and COPD. Adapted from [128-130]. 
Structural alterations Asthma COPD 
Predominant anatomic localization large airways small airways and alveoli 
Inflammatory cells mast cells, eosinophils, 
CD4+ T lymphocytes 
macrophages, neutrophils 
CD8+ T lymphocytes 
Epithelial shedding + + + - 
Goblet cell hyperplasia + + + + 
Squamaous cell metaplasia + + + + + 
Mucous gland hypertrophy + + + + + + + 
Reticular basement membrane thickening  + + + - 
Increased smooth muscle mass + + + (large airways) + + (small airways) 
Airway wall thickening + + + + (small airways) 
Airway wall fibrosis + (when severe) + + 
Angiogenesis and increased vascularity + + + 
Emphysema  - + + + 
 
  
1.4. ASTHMA AND COPD CURRENT THERAPY 
Inhaled corticosteroids 
Inhaled corticosteroids such as budesonide and fluticasone are the most effective anti-
inflammatory agents currently available for the long-term treatment of asthma [1]. They 
reduce symptoms through inhibition of inflammatory cell infiltration in the bronchial mucosa 
and decrease of pro-inflammatory mediators [242]. Their predominant anti-inflammatory 
© S. Goulet, 2006 34 
effect is to “switch off” inflammatory genes through the interaction between the activated 
glucocorticoid receptors (GR) and pro-inflammatory transcriptions factors, such as NF-κB 
(Fig. 1.5) [243-250]. Corticosteroids diffuse across cell membranes and bind to GR in the 
cytoplasm. In an unbound state, GR remain in the cytosol and are complexed to several 
different proteins including the chaperones heat shock protein 90 (Hsp90). On ligand binding, 
the GR undergo conformational changes and dissociate from Hsp90, leading to nuclear 
translocation of the corticosteroid-GR complexes. Then, corticosteroid-GR block histone 
acetylation at the site of inflammatory gene transcription, either by direct binding to NF-κB-
associated coactivators or by recruitment of HDAC-2, leading to suppression of activated 
inflammatory genes [251, 252]. 
 
 
Figure 1.5. “Switch off” of activated inflammatory genes by corticosteroids. Many inflammatory genes are 
activated by stimuli (IL-1β and TNF-α), resulting in activation of NF-κB, which translocates to the nucleus. NF-
κB binds to specific recognition sites in the promoter regions of responsive genes and subsequently recruits 
transcriptional coactivators, such as CBP and p300/CBP activating factor (PCAF), that have intrinsic acetyl 
transferase (HAT) activity, leading to increased transcription of inflammatory genes. Corticosteorids bind to GR 
in the cytosol. These complexes translocate to the nucleus and inhibit HAT by interacting with coactivators and 
by recruiting HDAC-2, leading to suppression of inflammatory genes. Figure by Barnes et al. [250].  
Corticosteroids may also “switch on” anti-inflammatory gene expression (Fig. 1.6). Activated 
corticosteroids-GR complexes translocate to the nucleus, form dimers and interact with 
glucocorticoid-response elements (GRE) in the promoter region of corticosteroids-sensitive 
genes. GR-GRE interactions lead to recruitment of coactivators molecules, such as CREB-
binding protein (CBP), resulting in histone acetylation, chromatin unwinding and 
transcription of genes encoding anti-inflammatory proteins [249, 253]. 
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Figure 1.6. “Switch on” of anti-inflammatory gene expression by corticosteroids. Corticosteroids bind to 
cytoplasmic GR and translocate to the nucleus, where the corticosteroids-GR complexes bind to GRE in the 
promoter region of corticosteroids-sensitive genes and bind to coactivator molecules with HAT activity, causing 
acetylation and activation of genes encoding anti-inflammatory proteins. Figure by Barnes et al. [250]. 
 
Airway inflammation in COPD is corticosteroids-resistant. High doses of corticosteroids have 
no effect on the inflammatory cells, cytokines profiles or proteases/antiproteases imbalance in 
COPD patients [117-119]. This lack of response may be secondary to increased oxidative 
stress as a result of cigarette smoking, leading to reduced HDAC-2 activity [120, 122]. 
Recently, the bronchodilator theophylline has been shown to stimulate HDAC activity in 
COPD, consequently restoring the anti-inflammatory actions of corticosteroids [254]. 
Inhaled LABA 
LABA such as formoterol and salmeterol are used as bronchodilators to bring rapid relief of 
airway bronchoconstriction. LABA exert their biological and therapeutic effects through the 
cell surface β2-adrenergic receptors, which are members of the G-protein-coupled receptor 
family. Ligand-binding involves activation of the Gs-protein that in turn activates adenyl 
cyclase. This process leads to production of cyclic adenosine monophosphate (cAMP) and 
subsequent activation of protein kinase A, which then phosphorylates intracellular regulatory 
proteins involved in the control of muscle tone, such as myosin light chain kinase. Increased 
cAMP also results in inhibition of intracellular calcium and calcium release, leading to ASMC 
relaxation [255]. Besides, LABA exhibit non-bronchodilatory properties such as inhibition of 
pro-inflammatory mediators release and prevention of plasma leakage [256, 257]. 
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Combination therapy 
The combination of corticosteroids and LABA results in better outcomes than higher doses of 
corticosteroids in asthma [258-260] and COPD [124, 125, 261] with better symptoms control 
and an additive or synergistic reduction of airway inflammation. Although much of the 
benefits of the combination likely are through their specific mechanisms of action (anti-
inflammatory versus bronchodilation), some of the additive effects may be due to the ability 
of LABA to enhance GR activation and nuclear translocation and to the ability of 
corticosteroids to increase β2-adrenergic receptor synthesis [257, 262-266]. 
Effect on airway remodeling 
Despite substantial evidence on the effect of inhaled corticosteroids on airway inflammation 
in asthma, data on remodeling are more limited and not clear [267]. While short-term 
corticosteroid treatment showed no significant change on the thickness of the reticular 
basement membrane [205, 268, 269] longer therapy resulted in a significant reduction 
mediated via decreased ECM deposition, growth factor and MMPs expression [154, 206, 270-
275]. Inhaled corticosteroids have also been shown to reduce airway submucosa vascularity in 
asthma [170, 276, 277]. In contrast to the inhibitory effect of corticosteroids on cell 
proliferation of ASMC derived from healthy subjects [278], the absence of C/EBPα appeared 
to be responsible for the enhanced proliferation of ASMC from asthma patients and might 
further explain the failure of corticosteroids to inhibit their proliferation in vitro [168, 279]. 
All these structural changes result in an overall airway wall thickness, which seems to be 
reduced by short-term treatment with inhaled corticosteroids in asthma [138].  
Less is known about the effect of LABA on airway remodeling. Briefly, LABA have been 
shown to reduce airway vascularity in asthma in vivo [280] and cell proliferation of healthy-
derived ASMC [281]. Finally, combination therapy has been shown to inhibit ASMC 
proliferation to a greater extent than each drug alone through synchronized activation of GR 
and C/EBPα [282]. The effect of corticosteroids and/or LABA on structural alterations in 
COPD is not yet investigated. All together, these studies suggest a potential therapeutic role 
of the current asthma and COPD therapy in reversing the airway remodeling process.  
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CHAPTER 2 
OBJECTIVES 
 
Prevalence of asthma and COPD is rapidly increasing worldwide. Both diseases result from 
chronic airway inflammation and tissue remodeling. Airway remodeling is characterized by 
various structural changes, including increased ECM deposition, more specifically of collagen 
and GAGs mainly synthesized by fibroblasts and ASMC. The basic therapy for asthma and 
COPD consists of corticosteroids and LABA, which are efficient at controlling symptoms, 
bronchoconstriction and inflammation but their effect at preventing or reversing lung tissue 
remodeling is unclear. 
Therefore, the general aim of this thesis was to develop a human cell culture based in vitro 
model of airway inflammation and tissue remodeling in order to investigate the modulation of  
ECM deposition by lung fibroblasts and ASMC and their response to the actual asthma and 
COPD therapy. 
The specific objectives of this thesis were: 
• To develop an in vitro model mimicking airway inflammation and active tissue repair. 
• To assess (i) the effect of corticosteroids and LABA, alone or in combination, on total 
ECM, collagen and GAGs deposition by primary human lung fibroblasts under non-
inflammatory and inflammatory conditions and (ii) the mechanisms potentially 
involved in the drug effect. 
• To investigate (i) the effect of corticosteroids and LABA on total ECM, collagen and 
GAGs deposition as well as gelatinolytic activity by primary human ASMC under 
non-inflammatory and inflammatory conditions and (ii) whether ASMC derived from 
asthma and COPD patients respond the same way as ASMC from healthy subjects. 
 
CHAPTER 3   
EFFECT OF CORTICOSTEROIDS AND LABA ON LUNG TISSUE REMODELING IN 
VITRO IN PRIMARY HUMAN LUNG FIBROBLASTS 
 
Asthma and COPD are characterized by chronic airway inflammation and tissue remodeling, 
which includes increased deposition of ECM components, such as collagen and GAGs mainly 
produced by fibroblasts. In turn, these ECM proteins influence cell proliferation, migration, 
synthesis of pro-inflammatory mediators and growth factors, which may further sustain the 
inflammatory and remodeling processes. Thus, the ECM is a dynamic structure playing a key 
role in lung tissue structural alterations. Unfortunately, in vivo this pathological remodeling is 
not prevented or reversed by the current anti-inflammatory drugs and bronchodilators. A 
better understanding on the regulation of ECM components in lung fibroblasts by different 
mediators involved in lung diseases and by the mainstay therapies might provide new 
potential targets to prevent airway remodeling in patients. Therefore, using primary human 
lung fibroblasts we investigated the effect of corticosteroids and LABA in relation to tissue 
remodeling. 
This chapter includes results of the following projects: 
• Opposite effect of corticosteroids and LABA on serum- and TGF-β1-induced ECM 
deposition by primary human lung fibroblasts. Manuscript accepted in the Journal of 
Cellular Physiology. 
• Effect of corticosteroids and LABA on serum- and TGF-β1-induced total GAGs 
secretion and deposition by primary human lung fibroblasts. Ongoing research project. 
These results were presented as poster-discussion (2006) and oral presentation (2005) at the 
American Thoracic Society International Conference (San Diego, California, USA) and the 
abstracts were published in Proceedings of the American Thoracic Society. 
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Abstract 
Asthma and chronic obstructive pulmonary disease are characterized by chronic airway 
inflammation and major structural lung tissue changes including increased extracellular 
matrix (ECM) deposition. Inhaled corticosteroids and long-acting β2-agonists (LABA) are the 
basic treatment for both diseases but their effect on airway remodeling remains unclear. In 
this study we investigated the effect of corticosteroids and LABA, alone or in combination, on 
total ECM and collagen deposition, gene expression, cell proliferation and IL-6, IL-8 and 
TGF-β1 levels by primary human lung fibroblasts. In our model, fibroblasts in 0.3% albumin 
represented a non-inflammatory condition and stimulation with 5% FCS and/or TGF-β1 
mimicked an inflammatory environment with activation of tissue repair. 5% FCS increased 
total ECM, collagen deposition, cell proliferation and IL-6, IL-8 and TGF-β1 levels. In 0.3% 
albumin corticosteroids reduced total ECM and collagen deposition, involving the 
glucocorticoid receptor (GR) and downregulation of collagen, Hsp47 and Fli1 mRNA 
expression. In 5% FCS corticosteroids increased ECM deposition, involving upregulation of 
COL4A1 and CTGF mRNA expression. LABA reduced total ECM and collagen deposition 
under all conditions partly via the β2-adrenergic receptor. In combination, the drugs had an 
additive effect in the presence or absence of TGF-β1 further decreasing ECM deposition in 
0.3% albumin whereas counteracting each other in 5% FCS. These data suggest that the effect 
of corticosteroids but not of LABA, on ECM deposition by fibroblasts is altered by serum. 
These findings imply that as soon as airway inflammation is resolved, long-term treatment 
with combined drugs may beneficially reduce pathological tissue remodeling. 
Introduction 
Prevalence of asthma and chronic obstructive pulmonary disease (COPD) is rising worldwide 
and both diseases are characterized by chronic airway inflammation often leading to 
irreversible structural changes of the lung. The airway remodeling features include increased 
micro-vascularization, vessel leakage, smooth muscle cell hyperplasia and hypertrophy, 
thickening of the lamina reticularis and increased interstitial extracellular matrix (ECM) 
deposition [1-6]. It is still not clear whether the pathological ECM deposition results from 
chronic airway inflammation or is a pre-condition that contributes to the inflammatory 
process. Several studies reported that an increase of collagen contributed to airway 
hyperresponsiveness and correlated with subepithelial fibrosis and the number of fibroblasts 
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in the submucosa of asthma patients [7-11]. Therefore, ECM synthesis and degradation by 
fibroblasts play an essential role in lung tissue homeostasis and repair. 
TGF-β1 contributes to the daily and pathological ECM turnover in the lung and also 
modulates cell proliferation, differentiation, migration and apoptosis [12, 13]. TGF-β1 
expression is increased in the bronchoalveolar lavage fluid and in the airways of patients with 
asthma [14-16] and in the airway epithelium of patients with COPD [17, 18]. TGF-β1 can 
function either as a pro- or anti-inflammatory cytokine on inflammatory cells and regulate 
ECM production mainly by fibroblasts located in the airway wall [19, 20]. In non-diseased 
human lung fibroblasts we previously reported that TGF-β1 increased IL-6 secretion and 
stimulated the synthesis of ECM proteins, specifically of collagens and glycosaminoglycans 
[21-23]. Studies have shown a significant correlation between the number of TGF-β1 positive 
cells, collagen synthesis and subepithelial fibrosis in asthma patients [15, 24, 25]. 
The current therapy for asthma and COPD consists of inhaled corticosteroids and long-acting 
β2-agonists (LABA), applied alone or in combination. The anti-inflammatory actions of 
inhaled corticosteroids are well characterized but their effect on airway remodeling in asthma 
is controversially discussed [26-30] and not well-studied in COPD [31]. Even though the 
combination of inhaled corticosteroids and LABA resulted in better improvement of clinical 
outcome in patients [32], its influence on ECM is incompletely understood.  
In this study, we used primary human lung fibroblasts to assess tissue remodeling, more 
specifically ECM deposition, in the early phase of lung inflammation and its modulation by 
corticosteroids and LABA. In this regard, an interesting report showed that the transcriptional 
program of serum-deprived primary human neonatal foreskin fibroblasts in response to 10% 
FCS was related to activation of wound healing processes, including cell migration, 
proliferation, inflammation and angiogenesis [33]. Another well-established model of wound 
healing and remodeling is the contraction of 3D collagen gels by fibroblasts and it was 
recently reported that both FCS and TGF-β1 significantly augmented collagen gel contraction 
in a concentration-dependent manner [34]. Based on these findings, we assumed that 
fibroblasts under serum-free condition reflected a non-inflammatory environment, whereas 
stimulation with 5% FCS and/or TGF-β1 mimicked an early stage of inflammation with vessel 
leakage, serum infiltration and activation of tissue repair. Under these two experimental 
conditions we investigated the effect of corticosteroids and LABA, alone or in combination, 
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on the release of pro-inflammatory markers, total ECM and collagen deposition, gene 
expression and cell proliferation. 
Materials and Methods 
Cell culture 
Primary fibroblasts were established from non-diseased peripheral lung tissue samples 
obtained from patients undergoing lung resection following approval by the ethics committee 
(Faculty of Medicine, University Hospital Basel). Cells were grown in RPMI 1640 (Cambrex 
Bio Science, Verviers, Belgium) supplemented with 10% FCS (Gibco BRL Invitrogen, Basel, 
Switzerland) and 1% MEM-vitamins (Cambrex Bio Science). Cells were treated with 
dexamethasone (Calbiochem, Lucerne, Switzerland), fluticasone, salmeterol 
(GlaxoSmithKline, London, UK), budesonide, formoterol (AstraZeneca, Lund, Sweden) and 
recombinant human TGF-β1 (Sigma, Schnelldorf, Germany). Prior to any stimulation 
fibroblasts were serum-deprived for 24 h in 0.3% human albumin. Fibroblasts between 
passages 3 and 6 were used for all experiments. 
IL-6, IL-8 and TGF-β1 levels 
Confluent serum-deprived fibroblasts were treated with corticosteroids and/or LABA (10-7 M) 
in 0.3% albumin or 5% FCS with or without TGF-β1 (2.5 ng/ml) for 48 h. Conditioned cell 
culture media were collected and IL-6, IL-8 (Orgenium, Helsinki, Finland) and TGF-β1 
(R & D Systems, Minneapolis, MN, USA) levels were determined by ELISA according to the 
manufacturer’s instructions. 
Total ECM and collagen deposition 
Total ECM and collagen deposition were assessed as previously described [21]. Into 24-well 
plates confluent serum-deprived fibroblasts were treated with corticosteroids and/or LABA 
(10-10 to 10-6 M) in 0.3% albumin or 5% FCS with or without TGF-β1 (0.1 to 5 ng/ml) in the 
presence of 1 µCi/ml [3H]-proline (Amersham, Little Chalfont, UK). To assess the signaling 
pathways, fibroblasts were pre-treated for 30 min with the glucocorticoid receptor (GR) 
antagonist RU486 (Sigma) or the β2-adrenergic receptor antagonist propranolol (Calbiochem) 
at 10-6 M before adding a corticosteroid or a LABA (10-7 M). [3H]-proline incorporation was 
measured by liquid scintillation counting 48 h after stimulation. 
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Total ECM and collagen deposition were calculated as follows: 1) cpm in solubilized ECM 
without collagenase was defined as “total ECM deposition”, 2) (cpm in supernatant without 
collagenase x 100) / (cpm in supernatant without collagenase + cpm in solubilized ECM 
without collagenase) was defined as “percentage of background”, and 3) cpm in supernatant 
with collagenase – (% background x cpm in supernatant with collagenase) was defined as 
“collagen deposition”. 
Reverse transcriptase-polymerase chain reaction 
Confluent serum-deprived fibroblasts were treated with corticosteroids and/or LABA (10-7 M) 
in 0.3% albumin or 5% FCS for 48 h. Total RNA was isolated using RNeasy Mini kit (Qiagen 
GmbH, Hilden, Germany) and reverse-transcribed using M-MLV Reverse Transcriptase 
(Promega, Madison, WI, USA). cDNA was amplified with the following primers (sense and 
antisense, respectively; MWG-Biotech, Ebersberg, Germany): β-actin (5’-GTACGTTGCTAT 
CCAGGCTGTGC-3’, 5’-TCAGGCAGCTCGTAGCTCTTCTC-3’, 335 bp), COL1A1 (5’-CC 
CCTGGCGCTGTCGGTCCTG-3’, 5’-GGGCGCCAAGGTCTCCAGGAACA-3’, 201 bp), 
COL1A2 (5’-CCCCCTGGCTTCGCTGGTGAGA-3’, 5’-TTGCCAGGGTAACCGCGCTCT 
C-3’, 343 bp), COL3A1 (5’-CCCTGCTGGTGCTCCCGGTCCT-3’, 5’-CAGCGGCTCCAA 
CACCACCACAG -3’, 397 bp), COL4A1 (5’-TGCCGGGCCTACTGGTCCAAGAG-3’, 5’-
GGGGCACGGTGGGATCTGAATG-3’, 477 bp), COL5A1 (5’-CCCCCGGCCCTACTGGT 
GAACC-3’, 5’-CGGGCGGGGTTCTGCTGCGT-3’, 783 bp), CTGF (5’-GTGGAGTATGTA 
CCGACGGCC-3’, 5’-ACAG GCAGGTCAGTGAGCACGC-3’, 588 bp), Hsp47 (5’-GCGCA 
GCAGCAAGCAGCACTAC’-3, 5’-CGCGCCCGTAGATGTCCTGGTCA-3’, 679 bp), and 
Fli1 (5’-CCGCGCCACCACCCTCTACA-3’, 5’-GGCCCGGCTCAGCTTGTCGTAAT-3’, 
486 bp). PCR conditions were initial denaturation at 95°C for 3 min then denaturation at 95°C 
for 30 sec, primer annealing at 58°C for 30 sec and extension at 72°C for 1 min for 20-25 
cycles, followed by a final extension at 72°C for 5 min. PCR reactions were size fractionated 
by electrophoresis on 1.5% agarose gel and visualized by ethidium bromide stain under UV 
light. The intensity of each band was analyzed by densitometry using NIH Image J software 
and the relative mRNA expression of target gene was normalized to the β-actin control. 
Cell proliferation 
Proliferation was measured by [3H]-thymidine incorporation. Fibroblasts (5000 cells/well) 
were seeded into 96-well plates, grown until 60% confluence and serum-deprived for 24 h in 
0.3% albumin. Cells were stimulated with 5% FCS and treated with corticosteroids and/or 
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LABA at 10-7 M in the presence of 2 µCi/ml [3H]-thymidine (Amersham). Incorporated [3H]-
thymidine was determined by liquid scintillation counting 30 h after stimulation. 
Statistical analysis 
Data are expressed as means ± SEM. Student’s t-test was performed and differences were 
considered statistically significant if P < 0.05 compared to control or as indicated. 
Results 
5% FCS and TGF-β1 increased the release of IL-6 and IL-8 
Confluent fibroblasts in 0.3% albumin secreted low levels of IL-6 (889 ± 514 pg/ml) and IL-8 
(85 ± 43 pg/ml) within 48 h and stimulation with 5% FCS significantly increased cytokine 
levels by 4.5-fold (P < 0.05) and 19-fold (P < 0.01), respectively (Fig. 3.1A,B). TGF-β1 
increased IL-6 and IL-8 levels in 0.3% albumin but did not reach significance compared to 
control. In the presence of 5% FCS TGF-β1 significantly augmented IL-6 (9819 ± 
3299 pg/ml) and IL-8 (8255 ± 3373 pg/ml) levels compared to non-treated cells (P < 0.05; 
Fig. 3.1A,B). Corticosteroids (dexamethasone, fluticasone and budesonide at 10-7 M) 
significantly reduced both spontaneous and FCS-induced IL-6 and IL-8 release by 
approximately 75% (P < 0.05), two LABA (salmeterol and formoterol at 10-7 M) had no 
effect, and their combinations resulted in similar decreases as observed with the 
corticosteroids alone (P < 0.05; Fig. 3.1C,D). Similar results were obtained in the presence of 
TGF-β1 (data not shown). The vehicle of the drugs, with a maximal final concentration of 
0.001% DMSO, had no effect on IL-6 or IL-8 secretion by fibroblasts. 
TGF-β1 and 5% FCS additively increased total ECM and collagen deposition 
In 0.3% albumin TGF-β1 significantly increased total ECM and collagen deposition in a dose-
dependent manner over a concentration range from 0.1 to 5 ng/ml (P < 0.05; Fig. 3.2A,B). 
Since 5% FCS initiated a pro-inflammatory response in primary human lung fibroblasts we 
investigated the effect of FCS on total ECM and collagen deposition. As depicted in 
Fig. 3.2C, 5% FCS alone significantly increased total ECM deposition by 3-fold compared to 
0.3% albumin (6375 ± 464 versus 2125 ± 187 cpm; P < 0.001). When combined, 5% FCS and 
TGF-β1 additively increased total ECM deposition compared to 5% FCS or TGF-β1 alone 
(P < 0.001; Fig. 3.2C). Similar effects were observed on collagen deposition (Fig. 3.2D). 
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Figure 3.1. 5% FCS and TGF-β1 increased IL-6 and IL-8 levels, which were decreased by corticosteroids 
but not LABA. Confluent serum-deprived fibroblasts were stimulated with 5% FCS and/or TGF-β1 (2.5 ng/ml) 
for 48 h. Supernatants were collected and (A) IL-6 and (B) IL-8 levels were determined by ELISA (n = 4 cell 
lines). Cells were treated with corticosteroids and/or LABA (10-7 M) in 0.3% albumin or 5% FCS and (C) IL-6 
and (D) IL-8 levels were measured (n = 3 cell lines, n = 1 for dexamethasone). Bars represent means ± SEM 
expressed as (A,B) pg/ml and as (C,D) % of control, where 0.3% albumin and 5% FCS were defined as 100%. 
*P < 0.05, **P < 0.01 and ***P < 0.001. 
 
© S. Goulet, 2006 63 
 
Figure 3.2. TGF-β1 and 5% FCS increased total ECM and collagen deposition. Confluent serum-deprived 
fibroblasts were stimulated with TGF-β1 (0.1 to 5 ng/ml) in 0.3% albumin for 48 h and (A) total ECM and (B) 
collagen deposition were determined by [3H]-proline incorporation (n = 2 cell lines). Cells were stimulated with 
5% FCS and/or 2.5 ng/ml TGF-β1 and (C) total ECM and (D) collagen deposition were determined (n = 8 cell 
lines). Bars represent means ± SEM expressed as cpm. *P < 0.05, **P < 0.01 and ***P < 0.001. 
 
Serum reversed the inhibitory effect of corticosteroids on total ECM and collagen 
deposition 
We evaluated the effect of corticosteroids (on total ECM and collagen deposition at 
concentrations from 10-10 to 10-6 M in the presence or absence of 5% FCS (Fig. 3.3). The data 
of [3H]-proline incorporation are expressed as percentage of change from control, where 
100% was defined as total ECM and collagen deposition in 0.3% albumin or 5% FCS. In 
0.3% albumin dexamethasone, fluticasone and budesonide decreased total ECM deposition in 
a dose-dependent manner with a significant maximal reduction of 32 ± 6%, 24 ± 5% and 34 ± 
4%, respectively, at 10-6 M (P < 0.001; Fig. 3.3A-C). Interestingly, in 5% FCS the effect of 
corticosteroids on total ECM deposition was opposite to the effect observed in 0.3% albumin 
at therapeutically relevant concentrations. Dexamethasone further increased the FCS-induced 
total ECM deposition by 24 ± 5% at concentrations ≥ 10-8 M (P < 0.01; Fig. 3.3A). 
Fluticasone increased the FCS-induced total ECM deposition by 17% from concentrations 
≥ 10-9 M but without a clear dose-dependent response (P < 0.05; Fig. 3.3B). Budesonide dose-
dependently increased the FCS-induced total ECM deposition by 15 ± 7% at 10-9 M, and up to 
30 ± 11% at 10-6 M (P < 0.05; Fig. 3.3C). Similarly to their effect on total ECM deposition, 
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corticosteroids decreased collagen deposition in 0.3% albumin, while increased it in 5% FCS 
(Fig. 3.3D-F). 
 
Figure 3.3. Opposite effects of corticosteroids on total ECM and collagen deposition depended on the 
presence of 5% FCS. Confluent serum-deprived fibroblasts were treated for 48 h with increasing concentrations 
(10-10 to 10-6 M) of (A,D) dexamethasone, (B,E)  fluticasone or (C,F) budesonide in 0.3% albumin or 5% FCS 
and total ECM and collagen deposition, respectively, were determined by [3H]-proline incorporation. Bars 
represent means ± SEM expressed as % of change from control, 0.3% albumin or 5% FCS. *P < 0.05, **P < 
0.01 and ***P < 0.001 (n = 5 cell lines). 
 
LABA reduced total ECM and collagen deposition  
The effect of LABA on total ECM and collagen deposition in the presence or absence of 
serum is shown in Fig. 3.4. In both 0.3% albumin and 5% FCS salmeterol and formoterol (10-
10
 to 10-6 M) significantly decreased total ECM deposition (P < 0.05; Fig. 3.4A,B) and 
collagen deposition (P < 0.05; Fig. 3.4C,D) compared to the respective controls. However, 
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there was no clear dose-dependent response and both LABA reached their maximal effect at a 
clinically relevant concentration of 10-9 M. Thus, in contrast to corticosteroids the inhibitory 
effect of LABA on total ECM and collagen deposition was not affected by the presence of 
serum. 
 
Figure 3.4. LABA decreased total ECM and collagen deposition in the presence or absence of serum. 
Confluent serum-deprived fibroblasts were treated for 48 h with increasing concentrations (10-10 to 10-6 M) of 
(A,C) salmeterol or (B,D) formoterol in 0.3% albumin or 5% FCS and total ECM and collagen deposition, 
respectively, were determined by [3H]-proline incorporation. Bars represent means ± SEM expressed as % of 
change from control, 0.3% albumin or 5% FCS. *P < 0.05, **P < 0.01 and ***P < 0.001 (n = 5 cell lines). 
 
Combination of corticosteroids and LABA showed an additive effect on total ECM and 
collagen deposition  
Based on the above described results we assessed the effect of the combination of 
corticosteroids and LABA, all at 10-7 M, on total ECM and collagen deposition (Fig. 3.5). In 
0.3% albumin all combinations significantly additively decreased total ECM deposition by 45 
to 55% compared to the respective controls (P < 0.001) or to each drug alone (P < 0.05; Fig. 
3.5A-C). Interestingly, in 5% FCS the addition of LABA reduced the corticosteroid-induced 
total ECM deposition close to control levels. Salmeterol counteracted the stimulatory effect of 
dexamethasone (17 ± 8 versus 48 ± 11%; P < 0.05; Fig. 3.5A) and fluticasone (30 ± 11 versus 
68 ± 11%; P < 0.05; Fig. 3.5B) on total ECM deposition. Formoterol also reduced the 
© S. Goulet, 2006 66 
budesonide-induced total ECM deposition (8 ± 11 versus 59 ± 11%; P < 0.01; Fig. 3.5C). The 
three drug combinations showed similar effects on collagen deposition. In 0.3% albumin 
combined corticosteroids and LABA further decreased collagen deposition compared to each 
drug alone, while in 5% FCS LABA completely prevented the corticosteroid-induced 
collagen deposition (Fig. 3.5D-F). 
 
Figure 3.5. Combined corticosteroids and LABA had an additive effect on total ECM and collagen 
deposition. Confluent serum-deprived fibroblasts were treated with corticosteroids and LABA (10-7 M), alone or 
in combination, for 48 h in 0.3% albumin or 5% FCS and [3H]-proline incorporation was determined. The 
following drug combinations were investigated: (A,D) dexamethasone and salmeterol (Dexa+Salm), (B,E) 
fluticasone and salmeterol (Fluti+Salm), and (C,F) budesonide and formoterol (Bude+Form) on total ECM and 
collagen deposition, respectively. Bars represent means ± SEM expressed as % of change from control, 0.3% 
albumin or 5% FCS. *P < 0.05, **P < 0.01 and ***P < 0.001 (n = 5 cell lines). 
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The additive effect of corticosteroids and LABA on TGF-β1-induced total ECM and 
collagen deposition 
Regarding the relevance of TGF-β1 for airway remodeling we investigated the effect of 
corticosteroids, LABA and their combination on TGF-β1-induced total ECM and collagen 
deposition in the presence or absence of serum (Fig. 3.6). The data are expressed as 
percentage of change from control, where 100% was defined as total ECM and collagen 
deposition after TGF-β1 (2.5 ng/ml) stimulation in 0.3% albumin or 5% FCS. In 0.3% 
albumin dexamethasone, fluticasone and budesonide significantly decreased the TGF-β1-
induced total ECM deposition by 29 ± 6% (P < 0.01), 29 ± 4% (P < 0.001) and 46 ± 5% 
(P < 0.001), respectively (Fig. 3.6A-C). The LABA, salmeterol and formoterol, significantly 
decreased the TGF-β1-induced total ECM deposition by 25 ± 2% and 45 ± 5%, respectively 
(P < 0.001). Combined corticosteroids and LABA further decreased the TGF-β1-induced total 
ECM deposition by a range from 51 ± 6% to 72 ± 4% compared to control (P < 0.001) or to 
each drug alone (P < 0.05; Fig. 3.6A-C). 
In 5% FCS dexamethasone, fluticasone and budesonide further enhanced the stimulatory 
effect of combined FCS and TGF-β1 on total ECM deposition by 29 ± 9% (P < 0.05), 36 ± 
7% (P < 0.001) and 33 ± 4% (P < 0.001), respectively (Fig. 3.6A-C). In contrast, salmeterol 
and formoterol significantly decreased the stimulatory effect of 5% FCS and TGF-β1 on total 
ECM deposition by 17 ± 3% and 40 ± 7%, respectively (P < 0.001). When combined, the 
drugs counterbalanced each other, the addition of LABA attenuating the stimulatory effect of 
corticosteroids on 5% FCS- and TGF-β1-induced total ECM deposition close to control levels 
(Fig. 3.6A-C). Similar results were observed for collagen deposition (Fig. 3.6D-F). 
Role of the GR and the β2-adrenergic receptor in the corticosteroid- and LABA-
mediated effect on total ECM and collagen deposition  
We investigated the role of the GR and the β2-adrenergic receptor in the effect of 
corticosteroids and LABA on total ECM and collagen deposition in the presence or absence 
of serum (Fig. 3.7). In 0.3% albumin the GR antagonist RU486 alone did not affect total ECM 
deposition but completely blocked the ECM decreasing effect of dexamethasone (104 ± 6 
versus 81 ± 5%; P < 0.01) or budesonide (102 ± 6 versus 71 ± 5%; P < 0.001) but had no 
significant effect on fluticasone (Fig. 3.7A). In the presence of 5% FCS RU486 alone 
significantly increased total ECM deposition compared to control (123 ± 6%; P < 0.01), 
however, it reduced the corticosteroid-increased total ECM deposition with a significant 
difference only for dexamethasone (116 ± 5 versus 139 ± 7%; P < 0.05; Fig. 3.7B). In 0.3% 
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albumin and 5% FCS the β2-adrenergic receptor antagonist propranolol alone did not affect 
total ECM deposition but partly altered the inhibitory action of formoterol and salmeterol 
(Fig. 3.7C,D). For collagen deposition, similar results were obtained (Fig. 3.7E-H). 
 
Figure 3.6. Additive effect of corticosteroids and LABA on TGF-β1-induced total ECM and collagen 
deposition. Confluent serum-deprived fibroblasts were treated with corticosteroids and LABA (10-7 M), alone or 
in combination, for 48 h in the presence of 2.5 ng/ml TGF-β1 in 0.3% albumin or 5% FCS and [3H]-proline 
incorporation was determined. The drug combinations investigated were: (A,D) Dexa+Salm, (B,E) Fluti+Salm 
and (C,F) Bude+Form on TGF-β1-induced total ECM and collagen deposition, respectively. Bars represent 
means ± SEM expressed as % of change from control, TGF-β1 stimulation in 0.3% albumin or 5% FCS. *P < 
0.05, **P < 0.01 and ***P < 0.001 (n = 5 cell lines). 
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Figure 3.7. The GR and the β2-adrenergic receptor are partly involved in the corticosteroid- and LABA-
mediated effect on total ECM and collagen deposition. Confluent serum-deprived fibroblasts were pre-treated 
for 30 min with RU486 or propranolol (10-6 M) before adding corticosteroids or LABA (10-7 M) in 0.3% 
albumin or 5% FCS for 48 h. (A-D) Total ECM and (E-H) collagen deposition were determined by [3H]-proline 
incorporation. Bars represent means ± SEM expressed as % of control, where 0.3% albumin and 5% FCS were 
defined as 100%. *P < 0.05, **P < 0.01, ***P < 0.001 (n = 3 cell lines). 
 
Effect of FCS and corticosteroids on TGF-β1 secretion 
Next we assessed whether the effect of serum and corticosteroids on ECM deposition 
correlated with TGF-β1 secretion. Therefore, we determined the level of active and total 
(active plus latent) TGF-β1 in conditioned media of fibroblasts treated with fluticasone  
(10-7 M) in 0.3% albumin or 5% FCS for 48 h (Fig. 3.8). Neither 0.3% albumin nor 5% FCS 
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medium contained any active TGF-β1, however following chemical activation 5% FCS 
medium contained 585 pg/ml of total TGF-β1 corresponding to its latent form (data not 
shown). As shown in Fig. 3.8A, fibroblasts in 0.3% albumin secreted 227 ± 69 pg/ml active 
and 396 ± 94 pg/ml total TGF-β1. Stimulation with 5% FCS significantly increased both 
active (464 ± 89 pg/ml) and total (1059 ± 202 pg/ml) TGF-β1 levels compared to 0.3% 
albumin (P < 0.01). Fluticasone treatment did not significantly modify TGF-β1 levels under 
both 0.3% albumin and 5% FCS conditions (Fig. 3.8A). 
Modulation of collagen, CTGF, Hsp47 and Fli1 mRNA expression by corticosteroids 
and LABA 
To further study the control mechanisms underlying the observed effect of cortico-steroids 
and LABA on total ECM and collagen deposition, we investigated the effect of budesonide 
and formoterol (10-7 M) on gene expression of different types of collagen and mediators 
involved in ECM synthesis (Fig. 3.8). Expression of the target genes was analyzed by 
densitometry analysis and normalized to β-actin and the relative gene expression from two 
cell lines is summarized in Table 3.1. As depicted in Fig. 3.8B by a representative PCR gel, 
budesonide downregulated COL1A1, COL1A2, COL3A1, COL5A1, heat shock protein 47 
(Hsp47) and Fli1 mRNA expression in 0.3% albumin within 48 h but had no effect on 
COL4A1 and CTGF. Formoterol had no clear effect on gene expression in 0.3% albumin. 
When added to budesonide formoterol did not further modulate the expression of our target 
genes as observed with budesonide alone under serum-free condition. 
Interestingly, we did not observe any upregulation in gene expression of collagens or ECM 
mediators when cells were stimulated with 5% FCS for 48 h. Furthermore, transcription of 
most collagen genes was not affected by budesonide, formoterol or their combination in the 
presence of 5% FCS. However, densitometry analysis revealed that budesonide alone or 
combined with formoterol in 5% FCS tended to increase COL4A1 compared to non-treated 
cells (Table 3.1). In addition budesonide upregulated CTGF, and downregulated Fli1 and to a 
smaller extent Hsp47 mRNA expression compared to control in 5% FCS. Formoterol 
decreased gene transcription of CTGF and had no effect on Hsp47 and Fli1 in 5% FCS. The 
addition of formoterol partly inhibited the effect of budesonide on CTGF mRNA expression 
but did not reach control level. In contrast, formoterol did not modulate the effect of 
budesonide on Hsp47 and Fli1 mRNA expression in the presence of 5% FCS (Fig. 3.8B). 
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Similar results were obtained with fluticasone and salmeterol under the same conditions 
(n = 2 cell lines; data not shown), suggesting a drug class effect on gene expression. 
 
Table 3.1. Relative collagen and ECM mediators mRNA expression. Relative expression measured by 
densitometry. Data represent means ± SEM expressed as % of control, where the relative mRNA expression 
(after normalization with β-actin) in non-treated primary human lung fibroblasts in 0.3% albumin was defined as 
100% (n = 2 cell lines, n =1 for Hsp47). 
 
 
Condition Control Budesonide Formoterol Budesonide + Formoterol 
COL1A1 0.3% albumin 5% FCS 
100 
104 ± 26 
64 ± 22 
92 ± 16 
100 ± 27 
121 ± 4 
52 ± 25 
88 ± 24 
COL1A2 
0.3% albumin 
5% FCS 
100 
98 ± 15 
84 ± 10 
82 ± 14 
103 ± 13 
111 ± 13 
69 ± 7 
80 ± 16 
COL3A1 
0.3% albumin 
5% FCS 
100 
93 ± 23 
58 ± 9 
83 ± 21 
128 ± 29 
134 ± 18 
61 ± 28 
95 ± 23 
COL4A1 0.3% albumin 5% FCS 
100 
112 ± 44 
153 ± 6 
194 ± 12 
100 ± 40 
99 ± 13 
107 ± 17 
181 ± 3 
COL5A1 0.3% albumin 5% FCS 
100 
101 ± 32 
72 ± 25 
86 ± 26 
101 ± 35 
116 ± 12 
68 ± 30 
84 ± 24 
CTGF 
0.3% albumin 
5% FCS 
100 
73 ± 11 
150 ± 46 
231 ± 22 
85 ± 13 
52 ± 20 
104 ± 37 
171 ± 47 
Hsp47 
0.3% albumin 
5% FCS 
100 
91 
30 
78 
76 
104 
27 
51 
Fli1 
0.3% albumin 
5% FCS 
100 
102 ± 16 
57 ± 15 
46 ± 15 
98 ± 9 
103 ± 8 
48 ± 9 
57 ± 26 
 
 
Corticosteroids and LABA decreased fibroblast proliferation  
We assessed the effect of corticosteroids and LABA (10-7 M) on cell proliferation in 
subconfluent fibroblasts by [3H]-thymidine incorporation (Fig. 3.8). 5% FCS significantly 
induced fibroblast proliferation compared to 0.3% albumin (10 952 ± 1020 versus 4250 ± 
796 cpm; P < 0.01; Fig. 3.8C), and this effect was significantly decreased by corticosteroids 
and LABA (P < 0.01) but did not reach significance for salmeterol (Fig. 3.8D). In 
combination, corticosteroids and LABA tended to have a stronger anti-proliferative effect 
compared to control (P < 0.01) but this additive effect was not significant when compared to 
each drug alone (Fig. 3.8D). 
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Figure 3.8. Possible mechanisms by which corticosteroids and LABA modify total ECM and collagen 
deposition. (A) Confluent serum-deprived fibroblasts were treated with fluticasone (10-7 M) for 48 h in 0.3% 
albumin or 5% FCS and active and total TGF-β1 levels in the conditioned media were measured by ELISA. Bars 
represent means ± SEM expressed as active and total TGF-β1 in pg/ml (n = 4 cell lines). (B) Confluent serum-
deprived cells were treated with budesonide and/or formoterol (10-7 M) in 0.3% albumin and 5% FCS and total 
RNA was isolated after 48 h. The PCR data are representative of two cell lines. (C,D) Subconfluent serum-
deprived fibroblasts were stimulated with 5% FCS, treated with corticosteroids and LABA (10-7 M), and cell 
proliferation was determined by [3H]-thymidine incorporation 30 h after stimulation. Bars represent means ± 
SEM expressed as (C) cpm or as (D) % of control, where 5% FCS was defined as 100% (n = 6 cell lines). 
**P < 0.01, ***P < 0.001. 
 
Discussion 
In this study we showed that serum significantly increased IL-6 and IL-8 levels as well as cell 
proliferation by primary human lung fibroblasts, and both pro-inflammatory cell responses 
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were inhibited by corticosteroids. FCS and TGF-β1 increased total ECM and collagen 
deposition significantly and showed an additive effect when combined. In addition, 
stimulation with 5% FCS increased TGF-β1 levels compared to serum-free condition. Under 
non-inflammatory condition corticosteroids inhibited total ECM and collagen deposition, 
involving the GR and downregulation of COL1A1, COL1A2, COL3A1, COL5A1, Hsp47 and 
Fli1 mRNA expression. In contrast, in the presence of serum corticosteroids significantly 
increased total ECM and collagen deposition, not involving the GR, TGF-β1 secretion or 
collagen gene transcription. LABA did not alter IL-6 and IL-8 levels but significantly reduced 
total ECM and collagen deposition regardless of the presence of serum. LABA also decreased 
the FCS-induced fibroblast proliferation. The effect of LABA on ECM deposition did not 
involve the β2-adrenergic receptor or collagen gene transcription. The combination of 
corticosteroids and LABA showed additive effects on total ECM and collagen deposition in 
the presence or absence of serum and was not affected by TGF-β1 stimulation. 
In the healthy lung, connective tissue fibroblasts are embedded in their specific local ECM 
and show low proliferation rate. We assumed that this condition can be mimicked by 
confluent layers of primary human lung fibroblasts under serum-free condition. It has been 
shown that serum starvation activates genes involved in the controlling mechanisms that 
maintain tissue homeostasis such as fat metabolism and negative cell-cycle control [33, 35]. 
Furthermore, Iyer et al. reported that under serum starvation gene expression of pro-
inflammatory cytokines such as IL-6 and IL-8 were downregulated and then upregulated by 
stimulation with serum [33], which we also observed in confluent primary human lung 
fibroblasts. Therefore, we assumed that serum in cell culture condition not only stimulates 
proliferation of subconfluent cells but also mimics inflammation in confluent cells. 
Surprisingly, none of the two studies mentioned above observed any effect of serum 
starvation or FCS stimulation on gene expression of ECM compounds as reported by others 
[36]. 
Increased levels of IL-6 and IL-8 were reported in lung inflammation and we and others have 
shown earlier that lung fibroblasts are a source of both cytokines especially when stimulated 
with TGF-β1 [23, 37, 38]. Based on our previous studies, we assessed the release of these two 
pro-inflammatory cytokines in response to serum and we showed that 5% FCS significantly 
increased IL-6 and IL-8 release by confluent fibroblasts compared to 0.3% albumin. In 
agreement with their anti-inflammatory properties [39], corticosteroids significantly 
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downregulated the spontaneous and FCS-induced release of both cytokines. However, the 
effect of LABA on pro-inflammatory mediators is controversially discussed and may depend 
on the cell type and stimulus [40-42]. Here, LABA alone did not affect IL-6 and IL-8 
secretion by fibroblasts, and in combination, LABA did not further modulate the decrease of 
the corticosteroids under both serum-free and 5% FCS conditions. 
Lung inflammation is associated with vessel leakage and consequently the surrounding tissue 
is exposed to non-physiological serum and growth factor levels which can stimulate ECM 
synthesis [25, 36]. Therefore, the effect of corticosteroids and LABA on total ECM and 
collagen deposition during lung inflammation is of interest. Accordingly in our in vitro model 
of inflammation and remodeling, TGF-β1 and 5% FCS significantly increased total ECM and 
collagen deposition by confluent fibroblasts. We cannot exclude that the FCS-induced 
increase of ECM deposition was partly mediated via TGF-β1. Indeed, increased levels of total 
TGF-β1 were measured in the conditioned media of confluent fibroblasts stimulated with 5% 
FCS for 48 h. 
Then we investigated the effect of corticosteroids on ECM deposition under both non-
inflammatory and inflammatory conditions. In 0.3% albumin corticosteroids dose-
dependently decreased total ECM and collagen deposition by fibroblasts, correlating with 
downregulation of COL1A1, COL1A2, COL3A1, and COL5A1 mRNA expression. It was 
previously reported that the decrease of collagen synthesis and mRNA by glucocorticoids is 
mediated via the GR [43]. In our model, the role of the GR in the corticosteroid-mediated 
effect on total ECM and collagen deposition in 0.3% albumin was partly confirmed as RU486 
counteracted the inhibitory effect of dexamethasone and budesonide on ECM deposition but 
not of fluticasone.  
To further elucidate the signalling mechanisms involved we assessed the effect of 
corticosteroids on CTGF, a well-described stimulus of ECM synthesis in mesenchymal cells 
[44, 45]. In 0.3% albumin CTGF mRNA expression was not affected by budesonide, 
suggesting that the inhibitory effect of corticosteroids on ECM deposition by fibroblasts under 
non-inflammatory condition is not mediated via CTGF. In 0.3% albumin budesonide 
downregulated mRNA expression of Hsp47, a chaperone protein critical for collagen 
maturation associated with type I procollagen expression [46, 47], indicating that 
corticosteroids may affect collagen conformation. We further investigated the effect of 
budesonide on Fli1, a member of the Ets transcription factors family that has been shown to 
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suppress collagen transcription in skin fibroblasts [48, 49]. This is the first study to report that 
primary human lung fibroblasts expressed Fli1 mRNA. However, Fli1 gene expression was 
downregulated by budesonide in 0.3% albumin and therefore suggests that Fli1 was not 
available to suppress collagen in lung fibroblasts under non-inflammatory condition. As a 
consequence, Fli1 can not mediate the ECM reducing effect of corticosteroids under serum-
free condition.  
Interestingly, the effect of corticosteroids on total ECM and collagen deposition by lung 
fibroblasts was different in the presence of serum, which we used as a model for inflammation 
and tissue repair. Accordingly, in our model 5% FCS significantly increased total ECM and 
collagen deposition by confluent fibroblasts and were further increased by corticosteroids. 
This corticosteroid effect only partly involved the GR and was not mediated by collagen gene 
expression. This assumption is further supported by the observation that RU486 alone 
significantly increased total ECM and collagen deposition in the presence of serum. RU486 
acts as a competitor for glucocorticoids and occupies the GR binding site, still the complex 
migrates to the nucleus and recognises the respective glucocorticoid response element in gene 
promoters but does not affect transcriptional activity [50]. In addition to its function as a 
direct transcription factor the GR interacts with other gene control proteins in the cytosol and 
the effect of RU486 on this mechanism has not been studied in extension [51]. Thus, our data 
suggest that the increasing effect of corticosteroids on total ECM and collagen deposition may 
occur at the post-transcriptional level.  
We further assessed possible signalling pathways by which corticosteroids could achieve their 
distinct serum-dependent effect on total ECM and collagen deposition. Our data indicate that 
corticosteroids do not affect TGF-β1 production or activation by primary human lung 
fibroblasts, therefore the effect of corticosteroids on FCS-induced total ECM and collagen 
deposition did not involve TGF-β1. Similar to the reported effect of dexamethasone on CTGF 
in different cell types [52, 53], budesonide increased CTGF mRNA expression in the presence 
of 5% FCS, which may subsequently stimulate collagen synthesis. In 5% FCS budesonide 
downregulated Hsp47 mRNA expression, implying that procollagen conformation may also 
be affected by corticosteroids under inflammatory condition. Furthermore, budesonide 
downregulated Fli1 mRNA expression in 5% FCS, suggesting that under this condition the 
corticosteroid-induced ECM deposition may result from the lack of Fli1. Indeed, in dermal 
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fibroblasts and scleroderma human skin Fli1 levels inversely correlated with collagen type I 
and contributed to uncontrolled ECM deposition [49]. 
Our in vitro findings may relate to clinical studies investigating the short- or long-term effect 
of inhaled corticosteroids on airway wall remodeling. The increased total ECM and collagen 
deposition by fibroblasts under inflammatory condition may explain why short-term 
corticosteroids treatment did not significantly change collagen expression in the bronchial 
mucosa of asthma patients [28, 29, 54]. We showed that only under serum-free condition 
corticosteroids reduced total ECM and collagen deposition, which may reflect the 
observations that long-term/high-dose treatment with inhaled corticosteroids significantly 
reduced airway remodeling [10, 27, 55]. Furthermore, our findings may provide the basis to 
understand why high-dose corticosteroids may cause skin atrophy in non-inflamed tissue as 
previously reported [56]. 
Surprisingly, the effect of LABA on ECM turnover has not been assessed extensively. In our 
study LABA significantly reduced total ECM and collagen deposition with similar efficacy 
regardless of the presence of serum. However, this inhibitory effect of formoterol and 
salmeterol was only partly mediated via the β2-adrenergic receptor and could not be explained 
by collagen gene transcription. Interestingly, in 5% FCS formoterol downregulated CTGF 
mRNA expression and may account for a subsequent decreased collagen deposition. 
Formoterol did not change Hsp47 or Fli1 mRNA expression under both serum-free and 5% 
FCS conditions. Thus, under inflammatory condition LABA seem to reduce ECM deposition 
by downregulating CTGF and not affecting the expression of the negative control element 
Fli1. In regard to remodeling, Roberts et al. reported no change in the sub-basement 
membrane collagen deposition after six weeks of salmeterol treatment in patients with stable 
asthma [57]. In contrast, three months treatment with salmeterol reduced vascular remodeling 
in asthma patients [58]. In summary the effect of LABA on remodeling has to be further 
investigated as the effects might either depend on the duration of therapy or may be cell type 
specific. 
While the combination of inhaled corticosteroids and LABA has a beneficial effect on asthma 
symptoms, its effect on airway remodeling is not clear. In our study combined corticosteroids 
and LABA had an additive effect on total ECM and collagen deposition under both 0.3% 
albumin and 5% FCS in the presence or absence of TGF-β1. Most importantly, in 5% FCS 
LABA inhibited the corticosteroid-induced ECM deposition. Moreover, formoterol 
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counteracted the budesonide-induced upregulation of CTGF mRNA expression in 5% FCS, 
which may partly explain the effect of LABA on corticosteroid-induced collagen deposition 
in the presence of serum. However, under both serum-free and 5% FCS conditions the effect 
of combined budesonide and formoterol on collagen, Hsp47 and Fli1 gene expression was 
similar to budesonide alone. It was reported in children with asthma that six weeks treatment 
with budesonide plus formoterol did not further reduce circulating procollagen levels 
compared to budesonide [59]. In a murine allergen-induced model of airway remodeling the 
combination of fluticasone and salmeterol over a period of two weeks significantly increased 
fibronectin and collagen in the airway wall compared to placebo or fluticasone [60]. These 
observations imply that under chronic inflammation, adding LABA to corticosteroids does not 
further reduce the remodeling process in the lung. However, the effect of the combined drugs 
was only studied over a short period and with limited conclusions for dose-efficacy in both 
studies implying the necessity of further clinical, cellular and molecular biology studies.  
In addition to total ECM and collagen deposition, cell proliferation is another important 
feature of tissue remodeling. In agreement with others [61], we observed a significant 
decrease of the 5% FCS-induced fibroblasts proliferation by corticosteroids and LABA, and 
have reported earlier that this effect was dose-dependent [62]. Thus, these findings make it 
unlikely that the corticosteroid-dependent increased total ECM and collagen deposition under 
inflammatory condition were directly linked to cell proliferation. 
In conclusion, our data suggest that the effect of corticosteroids on total ECM and collagen 
deposition depends on the presence of serum but is not affected by TGF-β1. We hypothesize 
that corticosteroids enhance ECM deposition in the initial phase of inflammation when serum 
infiltration is present. This increased ECM may be regarded as an attempt of fibroblasts to 
limit further infiltration of serum and inflammatory cells into the tissue and this effect would 
be further supported by corticosteroids. Our data indicate that the combination of 
corticosteroids and LABA whilst inflammation is present would counteract the corticosteroid-
induced ECM deposition and therefore, be the treatment of choice instead of higher doses of 
corticosteroids. Then, as soon as inflammation is significantly diminished, both classes of 
drugs would contribute to a reduction of ECM in the lung but their concentrations should be 
carefully adjusted to avoid continuous matrix decrease and tissue loss as side effects. Thus, 
our findings might have implications for the treatment of patients with asthma and COPD in 
regard to lung tissue remodeling. 
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3.2. EFFECT OF CORTICOSTEROIDS AND LABA ON FCS- AND TGF-β1-INDUCED 
TOTAL GAGs SECRETION AND DEPOSITION BY PRIMARY HUMAN LUNG 
FIBROBLASTS 
 
Background and Aims of the study  
Within the lung ECM, collagen and elastin fibers are embedded in a hydrated gel, often called 
the “ground substance”. Critical constituents of this matrix are GAGs, a family of highly 
charged polysaccharides that are ubiquitously distributed. There are different types of GAGs: 
heparin/heparan sulphate, chondroitin sulphate, dermatan sulphate, keratan sulphate and 
hyaluronic acid. Most GAGs, except hyaluronic acid, are usually covalently linked to a core 
protein with which they form proteoglycans. Both GAGs and proteoglycans are involved in 
many important biological functions including regulation of ECM water balance, cell 
adhesion, proliferation, migration and modulation of growth factor and cytokine activity [1], 
thus contributing to lung tissue stability by regulating its biomechanical and elastic properties 
[2, 3]. Each GAG can exist in different lengths of the polysaccharide chains and in turn, the 
length determines its function.  
In the lungs of asthma and COPD patients, the structure and composition of the ECM are 
altered as a result of uncontrolled airway wall remodeling. This pathology is characterized by 
increased deposition of ECM constituents including GAGs and proteoglycans [4-9]. Recently, 
proteoglycan deposition has been observed in the airways basement membrane in allergen-
challenged animal models of asthma [10, 11]. In chronically inflamed airway tissue, 
fibroblasts are assumed to represent the main activated cell type contributing to the excessive 
deposition of collagen and other ECM constituents [12, 13]. Accordingly, serum-stimulated 
[14] and mechanically-stimulated [15] fibroblasts from asthma patients have been shown to 
produce more proteoglycans than fibroblasts from healthy individuals. 
TGF-β1 is a potent stimulator of ECM synthesis in lung fibrotic processes [16, 17] and is 
increased in asthma and COPD [18-22]. Beside stimulating collagen production, TGF-β1 
regulates the synthesis of different GAGs and proteoglycans [23-25]. Previously, our group 
has demonstrated that the three isoforms of TGF-β stimulated synthesis and deposition of 
collagen and GAGs in primary human lung fibroblasts [26, 27]. 
© S. Goulet, 2006 83 
To this day, inhaled corticosteroids and LABA are the most effective drugs to control the 
clinical symptoms associated with asthma and COPD but very little is known about their 
potential effects on GAGs and proteoglycans within the human lung. Therefore, the aims of 
this study were: (i) to investigate total GAGs secretion and deposition by primary human lung 
fibroblasts under non-inflammatory and inflammatory conditions; (ii) to assess the effect of 
corticosteroids and LABA on total GAGs secretion and deposition; and (iii) to compare 
whether the combination of both drugs would result in a stronger effect than each drug 
individually. 
Experimental design 
Primary human lung fibroblasts in 0.3% albumin were used to mimic a non-inflammatory 
environment and were stimulated with 5% FCS and/or TGF-β1 to reproduce an inflammatory 
response with active tissue repair [28]. Confluent serum-deprived fibroblasts were stimulated 
with 5% FCS and/or TGF-β1 (2.5 ng/ml) and treated with corticosteroids and/or LABA at  
10-7 M for 48 h. Total GAGs secretion and deposition were determined by [3H]-glucosamine 
incorporation in the cell culture media and in the cell layer with deposited ECM as detailed in 
the Materials and Methods section (Annex). 
Results 
FCS and TGF-β1 increased total GAGs secretion and deposition 
We first assessed total GAGs secretion and deposition by fibroblasts under non-inflammatory 
and inflammatory conditions. The [3H]-glucosamine incorporation data for total GAGs 
secretion and deposition by fibroblasts in 0.3% albumin were defined as control and 
standardized to 100%. As depicted in Fig. 3.9A, 5% FCS and TGF-β1 alone significantly 
increased GAGs secretion by 232 ± 29% and 191 ± 23%, respectively, compared to control 
(p < 0.01). Stimulation with 5% FCS combined with TGF-β1 further increased GAGs 
secretion compared to non-stimulated cells in 0.3% albumin (254 ± 25%; p < 0.01) but the 
increase was not significant compared to each stimulus alone (Fig. 3.9A). 
Similar results were obtained for total GAGs deposition. Stimulation with 5% FCS and TGF-
β1 significantly induced GAGs deposition to the same extent compared to 0.3% albumin 
(188 ± 18% and 193 ± 18%, respectively; p < 0.01). The combination of 5% FCS and TGF-β1 
further increased GAGs deposition compared to control (228 ± 29%; p < 0.001) but the 
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increase was not additive compared to 5% FCS or TGF-β1 alone (Fig. 3.9B). Thus, 5% FCS 
and TGF-β1 enhanced total GAGs secretion and deposition to a similar extent in fibroblasts. 
 
Figure 3.9. Effect of 5% FCS and TGF-β1 on total GAGs secretion and deposition by primary human lung 
fibroblasts. Confluent serum-deprived fibroblasts were stimulated with 5% FCS and/or TGF-β1 (2.5 ng/ml) for 
48 h. (A) Total GAGs secretion and (B) deposition were determined by [3H]-glucosamine incorporation. Bars 
represent means ± SEM expressed as percentage of control, where 0.3% albumin was defined as 100% (n = 5-7 
cell lines). ** p < 0.01, *** p < 0.001. 
 
Effect of corticosteroids and LABA on total GAGs secretion and deposition 
We investigated the effect of corticosteroids (budesonide and fluticasone) and LABA 
(formoterol and salmeterol), alone or in combination, on total GAGs secretion and deposition 
by fibroblasts in the presence or absence of serum. The [3H]-glucosamine incorporation data 
are expressed as percentage of change from control, corresponding to the standardized values 
described above for total GAGs secretion and deposition in 0.3% albumin and 5% FCS. 
Under serum-free condition budesonide significantly decreased GAGs secretion by 24 ± 5% 
compared to control (p < 0.001; Fig. 3.10A). The LABA formoterol alone had no effect but 
significantly counteracted the effect of budesonide in 0.3% albumin (p < 0.01). In the 
presence of 5% FCS budesonide and formoterol, alone or in combination, had no effect on 
GAGs secretion compared to control (Fig. 3.10A). As shown in Fig. 3.10B, fluticasone in 
0.3% albumin significantly decreased GAGs secretion by 18 ± 5% compared to control 
(p < 0.01). Salmeterol alone had no effect on GAGs secretion while when combined with 
fluticasone, it partially reversed fluticasone’s inhibitory effect (11 ± 5%; p = 0.08; Fig. 
3.10B). Similarly to the other drugs, fluticasone, salmeterol and their combination had no 
clear effect on 5% FCS-induced total GAGs secretion by fibroblasts (Fig. 3.10B). 
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Figure 3.10. Effect of corticosteroids and LABA on total GAGs secretion and deposition in the presence or 
absence of serum. Confluent serum-deprived fibroblasts were treated with corticosteroids and LABA, alone or 
in combination (all at 10-7 M), in 0.3% albumin or 5% FCS for 48 h. The effect of (A,C) budesonide and/or 
formoterol (Bude/Form) and (B,D) fluticasone and/or salmeterol (Fluti/Salm) on total GAGs secretion and 
deposition were determined by [3H]-glucosamine-incorporation. Bars represent means ± SEM expressed as 
percentage of change from control, where 0.3% albumin and 5% FCS were defined as 100% (n = 6-7 cell lines). 
* p < 0.05, ** p < 0.01, *** p < 0.001. 
 
In regards to total GAGs deposition different effects of the drugs were observed. In 0.3% 
albumin budesonide significantly decreased GAGs deposition by 22 ± 5% compared to 
control (p < 0.01). Formoterol alone had no effect on GAGs deposition and did not alter the 
effect of budesonide (22 ± 5%; p < 0.01; Fig. 3.10C). On the other hand, in 5% FCS 
budesonide, formoterol and their combination significantly increased GAGs deposition by 20 
± 5% (p < 0.01), 11 ± 4% (p < 0.05) and 13 ± 6% (p < 0.05), respectively (Fig. 3.10C). 
Similarly, under serum-free condition fluticasone significantly decreased GAGs deposition by 
23 ± 3% compared to control (p < 0.001) and salmeterol alone had no effect nor did it 
modulate the decreasing effect of fluticasone (25 ± 3%; p < 0.001; Fig. 3.10D). As described 
above for GAGs secretion, neither fluticasone nor salmeterol had any significant effect on 5% 
FCS-induced GAGs deposition (Fig. 3.10D). Therefore, these findings suggest that 
corticosteroids decrease total GAGs secretion and deposition under serum-free condition 
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whereas they have no clear opposite effect in the presence of 5% FCS. LABA alone have no 
effect and do not modulate the effect of corticosteroids under both conditions. 
Effect of corticosteroids and LABA on TGF-β1-induced total GAGs secretion and 
deposition 
Since TGF-β1 is a key factor in ECM synthesis we investigated the effect of corticosteroids, 
LABA and their combination on TGF-β1-induced total GAGs secretion and deposition in the 
presence or absence of serum. The data are expressed as percentage of change from control, 
corresponding to total GAGs secretion and deposition after TGF-β1 stimulation in 0.3% 
albumin and 5% FCS (data from Fig. 3.9) that were standardized to 100%. As shown in Fig. 
3.11A, budesonide significantly decreased TGF-β1-induced GAGs secretion by 31 ± 9% (p < 
0.05) under serum-free condition. Formoterol alone had no effect but partially reduced the 
effect of budesonide, resulting in a non-significant decrease compared to control (24 ± 11%; 
p = 0.054). In 5% FCS budesonide, formoterol and their combination significantly decreased 
the TGF-β1-induced GAGs secretion by 24 ± 4% (p < 0.01), 13 ± 4% (p < 0.05) and 24 ± 9% 
(p < 0.05), respectively (Fig. 3.11A). As observed previously in 0.3% albumin, fluticasone 
significantly decreased TGF-β1-induced GAGs secretion by 32 ± 1% (p < 0.001) while 
salmeterol had no effect and only slightly attenuated the inhibitory effect of fluticasone (25 ± 
2%; p < 0.001; Fig. 3.11B). In 5% FCS fluticasone and/or salmeterol had no significant effect 
on TGF-β1-induced GAGs secretion (Fig. 3.11B). 
Similar effects were obtained on TGF-β1-induced total GAGs deposition. Under serum-free 
condition budesonide significantly decreased TGF-β1-induced GAGs deposition by 39 ± 8% 
(p < 0.01) but formoterol had no effect and did not modulate the inhibitory effect of 
budesonide (40 ± 8%; p < 0.01; Fig 3.11C). Fluticasone, salmeterol and their combination 
significantly decreased TGF-β1-induced GAGs deposition by 27 ± 3% (p < 0.01), 8 ± 3% 
(p < 0.05) and 33 ± 3% (p < 0.001) in 0.3% albumin (Fig. 3.11D). Interestingly, in the 
presence of 5% FCS all drugs slightly decreased the TGF-β1-induced GAGs deposition but 
their effects were not significant compared to control (Fig. 3.11C, D). These data suggest that 
the effect of corticosteroids on total GAGs secretion and deposition in 5% FCS is reversed by 
further stimulation with TGF-β1.  
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Figure 3.11. Effect of corticosteroids and LABA on TGF-β1-induced total GAGs secretion and deposition. 
Confluent serum-deprived fibroblasts were stimulated with TGF-β1 (2.5 ng/ml) and treated with corticosteroids 
and/or LABA (10-7 M) in 0.3% albumin or 5% FCS for 48 h. The effect of (A,C) Bude/Form and (B,D) 
Fluti/Salm on TGF-β1-induced total GAGs secretion and deposition were determined by [3H]-glucosamine-
incorporation. Bars represent means ± SEM expressed as percentage of change from control, where TGF-β1 
stimulation in 0.3% albumin and 5% FCS were defined as 100% (n = 4 cell lines). * p < 0.05, ** p < 0.01, *** p 
< 0.001. 
 
Discussion 
In this study, we showed that serum and TGF-β1 significantly increased total GAGs secretion 
and deposition by primary human lung fibroblasts. Under non-inflammatory condition 
corticosteroids inhibited GAGs secretion and deposition but LABA had no effect. However, 
LABA partly reversed the inhibitory effect of corticosteroids on GAGs secretion when the 
drugs were combined. In contrast, in 5% FCS corticosteroids and LABA had no significant 
effect on GAGs secretion but they increased GAGs deposition. Corticosteroids and/or LABA 
had similar effects on TGF-β1-induced total GAGs secretion and deposition under serum-free 
condition but in 5% FCS corticosteroids and LABA surprisingly decreased the TGF-β1-
induced total GAGs secretion and deposition compared to control.  
As we reported for total ECM and collagen deposition [28], here we observed that 5% FCS 
and TGF-β1 increased total GAGs secretion and deposition. Accordingly, a study by Ueki et 
al. showed that FCS dose-dependently increased the secretion of hyaluronic acid in a human 
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embryonic lung-derived fibroblast cell line [29]. Similarly, stimulation with 10% FCS 
upregulated total proteoglycan production by human lung fibroblasts compared to low-serum 
condition [30]. During pathological tissue remodeling, levels of cytokines and growth factors 
are increased and can further stimulate ECM production. One of the most potent pro-fibrotic 
mediators, TGF-β1, has been shown to increase the secretion and deposition of GAGs and 
proteoglycans by fibroblasts [23-25]. Thus, our data are in accordance with the well-described 
increased GAGs synthesis under inflammatory conditions and during tissue repair.  
Concerning the effects of the current mainstay drugs used in the therapy of asthma and 
COPD, our data suggest that corticosteroids reduced total GAGs secretion and deposition 
under serum-free condition and that their inhibitory effect was blocked or partially reversed in 
the presence of serum. In contrast, LABA alone had no significant effect regardless of the 
presence of serum. Combined drugs had an additive effect under serum-free condition and 
had a stimulatory effect similar to the one observed with corticosteroids in 5% FCS. Only few 
studies investigated the effect of asthma drugs on the regulation of GAGs synthesis. Silvestri 
et al. showed that both fluticasone and salmeterol downregulated the expression of 
hyaluronic-cellular adhesion molecule (H-CAM, CD44) in a human fetal lung fibroblast cell 
line under serum-free condition, which may slow down fibroblast migration and tissue repair 
[31]. Different pro-inflammatory stimuli enhance the synthesis of individual GAGs in 
fibroblasts. In primary human lung fibroblasts, it was reported that fluticasone reduced both 
constitutive and IL-1β/TNF-α-induced hyaluronic acid synthesis, that salmeterol alone had no 
effect and that their combination resulted in a marked inhibition of hyaluronic acid synthesis 
via hyaluronan synthase-2 mRNA [32]. Similarly, Todorova et al. showed that budesonide 
reduced FCS-induced proteoglycan production by lung fibroblasts, formoterol had no effect 
and their combination had a stronger effect than budesonide alone, which occurred primarily 
at the post-transcriptional level and without affecting cell proliferation [30]. Furthermore, an 
interesting study showed that during allergen exposure budesonide treatment increased the 
mean density of the proteoglycans biglycan and versican in the lung tissue [33]. Thus, the in 
vitro effects of corticosteroids and LABA on GAGs and proteoglycans synthesis are still 
controversial and may depend on the cell culture conditions.   
TGF-β1 is involved in lung tissue remodeling and we are the first to report on the effects of 
corticosteroids and LABA on TGF-β1-induced GAGs synthesis and deposition under non-
inflammatory and inflammatory conditions. We showed that corticosteroids significantly 
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decreased TGF-β1-induced total GAGs secretion and deposition and that LABA alone had no 
effect nor did they modulate the effect of corticosteroids under serum-free condition. In 5% 
FCS corticosteroids and LABA decreased TGF-β1-induced GAGs secretion and deposition. 
Our findings are partly in accordance with data presented by Todorova et al. at the American 
Thoracic Society meeting showing that the combination of budesonide and formoterol under 
low-serum condition decreased total TGF-β1-induced proteoglycan production in lung 
fibroblasts to a greater extent than each drug alone [34]. Furthermore, we demonstrated that in 
5% FCS stimulation with TGF-β1 reversed the effects of corticosteroids and LABA, 
suggesting a common signalling pathway underlying the drugs response to FCS and TGF-β1. 
In summary, this study showed that the inhibitory effect of corticosteroids on total GAGs 
secretion and deposition was reversed or blocked under inflammatory conditions. We 
demonstrated that LABA alone had no clear effect on GAGs secretion and deposition and that 
combined drugs produced the same effect as corticosteroids alone under both non-
inflammatory and inflammatory conditions. In regard to clinical aspects, our data imply that 
once the airway inflammation is attenuated by corticosteroids further treatment with 
corticosteroids alone or combined with LABA may decrease GAGs synthesis by resident 
fibroblasts, thereby reducing ECM deposition. On the other hand, if the inflammatory status 
of the patient is not controlled, corticosteroids and LABA may not have any effect on airway 
remodeling or may even stimulate ECM deposition by fibroblasts. The characterization of 
individual GAGs and analysis of synthases gene expression are currently under investigation. 
These may provide insight into the mechanisms underlying the different effects of 
corticosteroids and LABA on GAGs synthesis and deposition under non-inflammatory and 
inflammatory conditions. 
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CHAPTER 4 
EFFECT OF CORTICOSTEROIDS AND LABA ON LUNG TISSUE REMODELING IN 
VITRO IN PRIMARY HUMAN ASMC 
 
Asthma and COPD are characterized by chronic airway inflammation and remodeling. Lung 
tissue remodeling includes ASMC hyperplasia and hypertrophy, increased ECM deposition 
and proteases/antiproteases imbalance in the airways. ASMC have properties beyond 
constriction and relaxation, they also contribute to lung tissue ECM turnover and remodeling 
by secreting various ECM components, MMPs and TIMPs. The current therapies of asthma 
and COPD are inadequate in preventing or reversing tissue remodeling. Thus, a better 
understanding of the mechanisms regulating ECM synthesis and degradation will be helpful 
to design new therapeutic strategies targeting the remodeling process. Therefore, using 
primary human ASMC from healthy, asthma and COPD patients we investigated the effect of 
corticosteroids and LABA on tissue remodeling. 
This chapter includes results of the following three ongoing research projects: 
• Corticosteroids and LABA differently modulate the secretion and deposition of total 
GAGs by primary human ASMC: a comparison from healthy, asthma and COPD 
patients. 
• Effect of corticosteroids and LABA on gelatinolytic activity of primary human ASMC 
from asthma and COPD patients compared to healthy controls. 
• Effect of corticosteroids and LABA on total ECM and collagen deposition by primary 
human ASMC. 
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4.1. CORTICOSTEROIDS AND LABA DIFFERENTLY MODULATE TOTAL GAGs 
SECRETION AND DEPOSITION BY PRIMARY HUMAN ASMC: A COMPARISON FROM 
HEALTHY, ASTHMA AND COPD PATIENTS 
 
Background and Aims of the study 
Proteoglycans are macromolecules composed of a protein core and one or more covalently 
attached GAG chains. GAGs represent long unbranched polysaccharides consisting of a 
repeating disaccharide unit and are divided into heparin/heparan sulphate, chondroitin sulfate, 
dermatan sulphate, kermatan sulphate and hyaluronan. GAGs are involved in various 
important biological processes, including regulation of cell adhesion, differentiation, 
proliferation and migration, modulation of growth factor and cytokine activity and collagen 
fibrillogenesis [1]. Furthermore, GAGs have been shown to alter the viscoelastic and 
biomechanical properties of the lung connective tissue [2-4]. Therefore, alterations in GAGs 
content and distribution during lung development and pathological processes indicate their 
essential role in health and disease [5].  
Chronic airway inflammation in asthma and COPD often leads to irreversible structural 
changes of the lung. This tissue remodeling is characterized by ASMC hyperplasia and 
hypertrophy, thickening of the reticular basement membrane and increased deposition of 
collagen, fibronectin, tenascin and proteoglycans in the airways [6-9]. Indeed, an increase in 
the deposition of proteoglycans has been reported in asthmatic airways [10-14] and in 
allergen-challenged animal models of asthma [15, 16]. A positive correlation has been shown 
between airway responsiveness and deposited proteoglycans in the airway wall [11] as well as 
proteoglycan production by human lung fibroblasts [17]. In addition to fibroblasts, it was 
reported that ASMC synthesize GAGs and proteoglycans [18-20] but little is known about 
their regulation during inflammation.  
Inhaled corticosteroids and LABA are the cornerstone treatment for asthma and COPD, as 
they reduce symptoms and improve lung function. Whether these drugs reverse the structural 
alterations in the lung of asthma and COPD patients is still under active debate and needs 
further attention. After investigating the effect of corticosteroids and LABA on total GAGs 
secretion and deposition in primary human lung fibroblasts, we expanded our research to 
primary human ASMC and our collaboration with The Woolcock Institute (Sydney, 
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Australia) allowed us to further assess ASMC from asthma and COPD patients. Therefore, the 
aims of our study were: (i) to compare total GAGs secretion and deposition by ASMC from 
asthma and COPD patients with ASMC isolated from healthy individuals under non-
inflammatory and inflammatory conditions; and (ii) to investigate the effect of corticosteroids 
and LABA, alone or in combination, on total GAGs secretion and deposition by ASMC from 
healthy, asthma and COPD patients. 
Experimental design 
Primary ASMC were established as described in the Material and Methods section (Annex). 
Sub-confluent ASMC (80%) were serum-deprived for 24 h then incubated in 0.1% FCS to 
reflect a non-inflammatory environment or stimulated with 5% FCS thus imitating an 
inflammatory response with active tissue repair [21]. In addition, cells were treated for 24 h 
with corticosteroids and/or LABA (10-7 M) either in 0.1% or 5% FCS. Total GAGs secretion 
and deposition were determined by [3H]-glucosamine incorporation in the cell culture media 
and in the cell layer with deposited ECM (Annex).    
Results 
Total GAGs secretion and deposition by ASMC from healthy, asthma and COPD 
patients 
We first determined total GAGs secretion and deposition by ASMC from healthy, asthma and 
COPD patients under non-inflammatory and inflammatory conditions. The [3H]-glucosamine 
incorporation data are expressed in cpm. As shown in Fig. 4.1, there was no difference in 
GAGs secretion and deposition between ASMC from healthy, asthma and COPD patients 
under non-inflammatory condition. Serum stimulation increased GAGs secretion compared to 
serum-free condition and reached significance only in ASMC from asthma patients (Fig. 
4.1A) but had no clear effect on GAGs deposition (Fig. 4.1B). Thus, there was no difference 
in total GAGs secretion and deposition by ASMC from asthma and COPD patients compared 
to ASMC from healthy controls and they similarly responded to serum stimulation. 
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Figure 4.1. Total GAGs secretion and deposition by primary ASMC from healthy, asthma and COPD 
patients. Sub-confluent serum-deprived ASMC from healthy, asthma and COPD subjects were stimulated in 
0.1% FCS or 5% FCS for 24 h. (A) Total GAGs secretion and (B) deposition were determined by [3H]-
glucosamine incorporation. Bars represent means ± SEM expressed in cpm (healthy, n = 5; asthma, n = 5; 
COPD, n = 2 cell lines). ** p < 0.01. 
 
Effect of corticosteroids and LABA on total GAGs secretion 
We then evaluated the effect of corticosteroids (budesonide and fluticasone) and/or LABA 
(formoterol and salmeterol) on total GAGs secretion after 24 h under non-inflammatory and 
inflammatory conditions. The [3H]-glucosamine incorporation data are expressed as 
percentage of change from control, which correspond to the cpm values obtained in Fig. 4.1 
without drugs treatment and standardized to 100%. As shown in Fig. 4.2A, under serum-free 
condition budesonide significantly decreased GAGs secretion by ASMC from healthy 
subjects (12 ± 3%; p < 0.01) while formoterol alone had no effect but partly reversed the 
effect of budesonide. In the presence of 5% FCS budesonide, formoterol and their 
combination had a tendency to decrease GAGs secretion compared to control (Fig. 4.2A). As 
depicted in Fig. 4.2B, fluticasone and/or salmeterol had similar effects than budesonide and/or 
formoterol on total GAGs secretion in ASMC from healthy individuals. In 0.1% FCS 
fluticasone significantly decreased GAGs secretion by 13 ± 2% (p < 0.01), salmeterol had no 
effect and the drugs combination resulted in the same decrease as observed with fluticasone 
alone (15 ± 3%; p < 0.01; Fig. 4.2B). Interestingly, these inhibitory effects were more 
important in the presence of 5% FCS. Indeed, fluticasone, salmeterol and their combination 
significantly reduced GAGs secretion by 26 ± 1% (p < 0.001), 14 ± 5% (p < 0.05) and 
21 ± 8% (p < 0.05), respectively (Fig. 4.2B). 
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Figure 4.2. Effect of corticosteroids and/or LABA on total GAGs secretion by primary ASMC. Sub-
confluent serum-deprived ASMC from healthy, asthma and COPD patients were treated with corticosteroids 
and/or LABA (10-7 M) in 0.1% or 5% FCS for 24 h and total GAGs secretion was determined by [3H]-
glucosamine incorporation. The following drug combinations were investigated: budesonide (Bude) and/or 
formoterol (Form) and fluticasone (Fluti) and/or salmeterol (Salm) in ASMC from (A, B) healthy, (C, D) asthma 
and (E, F) COPD patients, respectively. Bars represent means ± SEM expressed as percentage of change from 
control, which correspond to [3H]-glucosamine incorporation of untreated cells in 0.1% and 5% FCS 
standardized to 100% (healthy, n = 5; asthma, n = 5; COPD, n = 2 cell lines). * p < 0.05, ** p < 0.01, *** p < 
0.001. 
 
In comparison to ASMC from healthy individuals, asthma patients-derived ASMC appeared 
to be more responsive to corticostereoids and/or LABA. Under serum-free condition 
budesonide significantly decreased GAGs deposition by 17 ± 6% (p < 0.05), formoterol alone 
had no effect and slightly modulate the inhibitory effect of budesonide (11 ± 4%; p < 0.05; 
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Fig. 4.2C). In 5% FCS GAGs secretion was significantly reduced by budesonide (30 ± 4%; 
p < 0.001), formoterol (10 ± 1%; p < 0.001) and their combination (15 ± 4%; p < 0.01; 
Fig. 4.2C). Similarly, in 0.1% FCS fluticasone significantly decreased GAGs secretion by 
17 ± 5% (p < 0.01), salmeterol had no effect and did not modulate the effect of fluticasone (13 
± 5%; p < 0.05; Fig. 4.2D). In the presence of 5% FCS fluticasone, salmeterol and the drug 
combination significantly decreased total GAGs secretion by 33 ± 3%, 14 ± 2% and 24 ± 4%, 
respectively (p < 0.001; Fig. 4.2D), to a higher extent compared to the inhibitory effect 
observed in 0.1% FCS.  
Similar effects were observed in ASMC from COPD patients. Under serum-free condition 
budesonide significantly decreased GAGs secretion by 18 ± 3% (p < 0.05), formoterol alone 
had no effect and did not reverse the effect to budesonide (14 ± 5%; p < 0.05; Fig. 4.2E). In 
5% FCS budesonide and formoterol significantly reduced GAGs secretion by 25 ± 4% 
(p < 0.01) and 11 ± 2% (p < 0.05), respectively. Combined budesonide and formoterol also 
decreased GAGs secretion (20 ± 12%) but the effect did not reach significance due to a high 
variability between the two cell lines investigated (Fig. 4.2E). Similarly, under both serum-
free and 5% FCS conditions fluticasone decreased GAGs secretion by 24% in average (p < 
0.05 only in 5% FCS), salmeterol alone had no clear effect but slightly reversed the inhibitory 
effect of fluticasone (Fig. 4.2F). Thus, ASMC from asthma and COPD patients had similar 
responses to corticosteroids and LABA as healthy-derived ASMC under both non-
inflammatory and inflammatory conditions. 
Effect of corticosteroids and LABA on total GAGs deposition 
We then assessed the effect of corticosteroids and/or LABA on total GAGs deposition by 
ASMC from healthy, asthma and COPD patients in the presence or absence of serum. In 
ASMC from healthy individuals under serum-free condition budesonide significantly 
decreased GAGs deposition by 14 ± 3% (p < 0.01), formoterol alone had no effect but further 
modulated the inhibitory effect of budesonide (29 ± 6%; p < 0.01; Fig. 4.3A). In 5% FCS 
neither budesonide nor formoterol had an effect on GAGs deposition but their combination 
had a significant decreasing effect (10 ± 3%; p < 0.05; Fig. 4.3A). Comparable results were 
obtained with fluticasone and salmeterol. Under serum-free condition fluticasone significantly 
inhibited GAGs deposition by 19 ± 3% (p < 0.001), salmeterol alone had no clear effect and a 
stronger reduction was observed by the combined drugs (28 ± 2%; p < 0.001; Fig. 4.3B). 
None of fluticasone and salmeterol, alone or in combination, had a significant effect on GAGs 
deposition in the presence of serum (Fig. 4.3B). 
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 Figure 4.3. Effect of corticosteroids and/or LABA on total GAGs deposition by primary ASMC. Sub-
confluent serum-deprived ASMC from healthy, asthma and COPD patients were treated with corticosteroids 
and/or LABA (10-7 M) in 0.1% or 5% FCS and total GAGs deposition was determined by [3H]-glucosamine 
incorporation. The drug combinations investigated were budesonide (Bude) and/or formoterol (Form) and 
fluticasone (Fluti) and/or salmeterol (Salm) in ASMC from (A, B) healthy, (C, D) asthma and (E, F) COPD 
patients, respectively. Bars represent means ± SEM expressed as percentage of change from control, which 
correspond to [3H]-glucosamine incorporation of untreated cells in 0.1% and 5% FCS standardized to 100% 
(healthy, n = 5; asthma, n = 5; COPD, n = 2 cell lines). * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
In ASMC from asthma patients similar results were observed. Under serum-free condition 
budesonide significantly decreased GAGs deposition by 14 ± 3% (p < 0.01), formoterol alone 
had no effect but significantly enhanced the inhibitory effect of budesonide (20 ± 2%; 
p < 0.001; Fig. 4.3C). In 5% FCS only the combination of budesonide and formoterol 
significantly decreased GAGs deposition (13 ± 3%; p < 0.01; Fig. 4.3C). Similarly, in 0.1% 
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FCS fluticasone significantly inhibited GAGs deposition (19 ± 4%; p < 0.001), salmeterol 
alone had no clear effect but slightly modulated the effect of fluticasone (24 ± 3%; p < 0.001; 
Fig. 4.3D). None of the treatments had any effect on GAGs deposition in 5% FCS-stimulated 
cells (Fig. 4.3D). 
As depicted in Fig. 4.3E and F, in ASMC from COPD patients under serum-free condition 
budesonide and fluticasone significantly inhibited GAGs deposition by 23 ± 5% (p < 0.05) 
and 26 ± 3% (p < 0.01), respectively. Formoterol and salmeterol tended to decrease GAGs 
deposition but did not modulate the inhibitory effect of the corticosteroids. In contrast, no 
clear effect was obtained with any treatment in the presence of 5% FCS (Fig. 4.3E, F). 
Together, these findings showed that only corticosteroids under non-inflammatory conditions 
significantly decreased total GAGs deposition by ASMC from healthy, asthma and COPD 
patients. 
Discussion 
In this study our findings indicate no difference in the constitutive total GAGs secretion and 
deposition between ASMC from healthy, asthma and COPD patients and that serum 
stimulation had the tendency to increase total GAGs secretion. Under non-inflammatory 
condition corticosteroids significantly inhibited total GAGs secretion and deposition while 
LABA had no clear effect nor significantly modulated the effect of corticosteroids. Upon 
inflammatory stimulation corticosteroids significantly decreased GAGs secretion to a greater 
extent than LABA and their combination had a similar effect than corticosteroids alone. On 
the other hand, corticosteroids and/or LABA had no clear effect on total GAGs deposition in 
the presence of serum.  
It is well documented that in the airways of asthma patients there is an increase in the number 
of ASMC [22] as well as an increase in the amount of total ECM surrounding ASMC in the 
connective tissue [23]. More profound examinations revealed an increase in hyaluronan and 
versican within and around the smooth muscle bundles, suggesting increased synthesis of 
specific GAGs and proteoglycans by ASMC from asthma patients [24]. ASMC can promote 
the formation of the interstitial ECM and ASMC derived from asthma or COPD patients may 
respond differently than cells from healthy individuals, both qualitatively and quantitatively 
[25, 26]. Interestingly, our findings showed that there were more GAGs secreted that 
deposited by ASMC from healthy, asthma and COPD patients but no difference in total 
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GAGs secretion and deposition between the three groups. We previously described that serum 
stimulation mimicked an inflammatory response in vitro and increased total ECM, collagen 
and GAGs deposition in primary non-diseased human lung fibroblasts [21, 27]. Here, we 
showed that serum stimulation slightly increased total GAGs secretion but not GAGs 
deposition and to a lower extent compared to fibroblasts as previously described.  
Airway remodeling in chronic asthma and COPD may be viewed as a consequence of 
inflammation, resulting in release of cytokines and growth factors causing in turn, activation 
of fibroblasts and ASMC to produce more ECM macromolecules [19, 20, 28, 29]. 
Interestingly, Johnson et al. reported that passive sensitization of ASMC with serum from 
asthma patients significantly increased ECM production, including perlecan and chondroitin 
sulfate, but was not affect by beclomethasone treatment [18]. To our knowledge, this study is 
the only available on the effect of corticosteroids on GAGs synthesis by human ASMC. Our 
findings showed that corticosteroids significantly decreased total GAGs secretion by ASMC 
stimulated with 0.1% or 5% FCS. Interestingly, we demonstrated that corticosteroids 
decreased total GAGs deposition only under serum-free condition and had no effect in the 
presence of serum, which is in accordance with the study of Johnson et al. In addition, the 
effects of corticosteroids were not modulated by the combination with LABA under non-
inflammatory and inflammatory conditions.  
Preliminary data presented at the World Congress of Pharmacology held last July in Beijing, 
China, provide evidences that ASMC synthesized hyaluronic acid, heparin sulfate, dermatan 
sulfate and chondroitin sulfate [30]. There was no difference in the composition of GAGs 
between ASMC from healthy and asthma subjects. However, the levels of secreted hyaluronic 
acid were decreased by budesonide while they were increased by formoterol and to a greater 
extent by the drugs combination in ASMC from healthy and asthma patients. Thus, although 
total GAGs secretion and deposition by ASMC from healthy, asthma and COPD patients were 
similarly affected by corticosteroids and LABA, individual GAG may be differently regulated 
under non-inflammatory and inflammatory conditions.  
In conclusion, our data indicate no difference in total GAGs secretion and deposition by non-
treated ASMC from healthy, asthma and COPD patients in the presence or absence of serum. 
Corticosteroids decreased GAGs secretion under non-inflammatory and inflammatory 
conditions and were not modulated by LABA. Total GAGs deposition was decreased by 
corticosteroids under serum-free condition while not affected by the drugs in 5% FCS. These 
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findings imply that ASMC from healthy, asthma and COPD patients responded similarly to 
FCS, corticosteroids and/or LABA. The characterization of individual GAGs, the levels of 
hyaluronic acid in ASMC-conditioned media and the mRNA expression of GAGs synthases 
following the different treatments are in progress. These results will point out which GAGs 
are modulated by corticosteroids and/or LABA and which mechanisms may regulate their 
effects. 
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4.2. EFFECT OF CORTICOSTEROIDS AND LABA ON GELATINOLYTIC ACTIVITY OF 
PRIMARY HUMAN ASMC FROM ASTHMA AND COPD PATIENTS COMPARED TO 
HEALTHY CONTROLS 
 
Background and Aims of the study 
In healthy individuals the physiologic turnover of total ECM in the airways has been 
estimated between 10 to 15% per day and results from the balance between the synthesis and 
degradation of ECM constituents controlled by MMPs and their inhbitors TIMPs [1]. Studies 
have suggested that in chronic inflammatory lung diseases, the proteases/antiproteases 
balance is altered. Indeed, enhanced MMPs expression has been reported in bronchial 
biopsies, serum, sputum and BALF of asthma and COPD patients [2-8]. In the lung MMPs 
are expressed by inflammatory and mesenchymal cells and play a key role in lung tissue 
homeostasis and remodeling [1, 9-12]. Although MMPs are being increasingly investigated in 
airway cell biology, little is known about the regulation of ASMC-derived MMPs in 
inflammatory lung diseases and the potential effect of corticosteroids and LABA. Therefore, 
the aims of this study were: (i) to compare MMPs secretion and activity kinetics by primary 
ASMC from healthy subjects to those of ASMC from asthma and COPD patients; and (ii) to 
determine the effect of corticosteroids and LABA, alone or in combination, on MMPs activity 
in ASMC obtained from healthy, asthma and COPD subjects.  
Experimental design 
Confluent serum-deprived ASMC were treated with the corticosteroid budesonide and/or the 
LABA formoterol (both at 10-8 M) in 0.1% FCS for 0.5, 1, 6 and 24 h. Conditioned media 
were collected, equalized for protein content and MMPs activity was determined by gelatin 
zymography (Annex). 
Results 
Gelatinolytic activity of ASMC from healthy, asthma and COPD patients 
Zymograms of ASMC-conditioned media showed that growth-arrested cells under serum-free 
condition constitutively secreted the 72-kDa gelatinase proMMP-2 but not the 92-kDa 
gelatinase proMMP-9 (Fig. 4.4A). Other faint bands at higher molecular weight were also 
detectable and may correspond to proMMP-2 dimers or complexes of proMMP-2 with other 
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MMPs and/or TIMPs. No gelatinase activity was detected in 0.1% FCS medium alone 
(Fig. 4.4A). The gelatinolytic activity data are expressed as arbitrary densitometry units (a.u.). 
As depicted in Fig. 4.4B, proMMP-2 activity was significantly decreased in ASMC of asthma 
(8058 ± 115 a.u.; p < 0.01) and COPD patients (8190 ± 500 a.u.; p < 0.05) compared to 
ASMC of healthy individuals after 0.5 h incubation in 0.1% FCS (10 500 ± 307 a.u.). These 
values were defined as control and standardized to 100% for further analysis. 
 
 
Figure 4.4. Gelatinolytic activity of ASMC from healthy, asthma and COPD patients. Confluent serum-
deprived ASMC from healthy, asthma and COPD subjects were incubated in 0.1% FCS for 0.5, 1, 6 and 24 h 
and conditioned media were analyzed for MMPs activity by zymography. (A) Gelatinolytic activity in 
conditioned media of ASMC. (B) ProMMP-2 activity after 0.5 h incubation defined as control and standardized 
to 100%. (C) Time-kinetic of proMMP-2 production. Bars represent means ± SEM expressed as arbitrary 
densitometry units (B) and percentage (C). Representative zymograms are shown (healthy, n = 3; asthma, n = 2; 
COPD, n = 3 cell lines). * p < 0.05, ** p < 0.01. 
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We then investigated the kinetic of proMMP-2 gelatinolytic activity over 24 h and the 
following data are expressed as percentage. As displayed in Fig. 4.4C, proMMP-2 activity 
increased with time and a similar profile was observed in ASMC originating from healthy, 
asthma or COPD patients. In ASMC from healthy subjects proMMP-2 activity was 
significantly enhanced to 187 ± 12% after 24 h incubation in 0.1% FCS (p < 0.01). Compared 
to ASMC from healthy individuals, the autocrine production of proMMP-2 increased faster in 
the asthmatic cells, reaching 121 ± 9% after 1 h incubation and up to a significant increase of 
229 ± 8% after 24 h compared to control (p < 0.05). In ASMC from COPD patients proMMP-
2 activity was enhanced to 136 ± 3 and 213 ± 19% after 6 and 24 h incubation, respectively (p 
< 0.05; Fig. 4.4C). Thus, our data demonstrated that ASMC from asthma and COPD patients 
constitutively secreted less proMMP-2 than ASMC from healthy subjects but increased 
similarly with time. 
Effect of corticosteroids and LABA on gelatinolytic activity of ASMC 
We investigated the effect of budesonide and formoterol on the constitutive proMMP-2 
secretion by ASMC. Budesonide and formoterol alone or in combination had no significant 
effect on proMMP-2 gelatinolytic activity of ASMC from healthy, asthma and COPD patients 
compared to non-treated cells after 0.5, 3 and 6 h incubation (Fig. 4.5). However, combined 
drugs tended to reduce proMMP-2 secretion by ASMC from COPD patients after 24 h 
incubation but this decrease failed to reached significance when compared to non-treated cells 
(169 ± 26 versus 213 ± 19%; p = 0.068; Fig. 4.5C). Thus, our findings showed no significant 
effect on proMMP-2 gelatinolytic activity by corticosteroids and LABA in ASMC from 
healthy, asthma and COPD patients. 
Discussion 
In this study, we investigated the effect of corticosteroids and LABA on gelatinolytic activity 
of ASMC originating from healthy, asthma and COPD patients. We showed that only 
proMMP-2 was constitutively secreted by ASMC and that proMMP-2 activity was 
significantly decreased in ASMC from asthma and COPD patients compared to healthy 
individuals but all similarly increased in a time-dependent manner. However, proMMP-2 
secretion was not significantly affected by budesonide and formoterol, alone or in 
combination. 
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Figure 4.5. Effect of budesonide and formoterol on gelatinolytic activity. Confluent serum-deprived ASMC 
were treated with budesonide (bude) and/or formoterol (form) at 10-8 M in 0.1% FCS for 0.5, 1, 6 and 24 h. 
Gelatinolytic activity in conditioned media of ASMC from (A) healthy, (B) asthma and (C) COPD patients was 
determined by zymography. Bars represent means ± SEM expressed as percentage, with proMMP-2 activity of 
non-treated ASMC after 0.5 h incubation being strandardized to 100%. Representative zymograms are shown 
(healthy, n = 3; asthma, n = 2; COPD, n = 3 cell lines). 
 
In the conditioned media of confluent ASMC under serum-free condition we detected 
gelatinolytic activity of proMMP-2 only. Previously published studies showed that ASMC 
constitutively released the 72-kDa gelatinase and further reported secretion of the 92-kDa 
gelatinase proMMP-9 when stimulated with pro-inflammatory mediators such as TNF-α [9, 
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13]. More recent studies reported that human ASMC express and secrete a spectrum of 
MMPs, including  MMP-1, MMP-2, MMP-3, MMP-12 and MT1-MMP as well as their 
inhibitors TIMP-1 and TIMP-2 [14-18]. Furthermore, it was shown that upon stimulation with 
FCS or asthmatic serum MMPs secretion by ASMC from healthy individuals was upregulated 
[13, 15]. Therefore, it would be interesting to study modulation of different MMPs and 
TIMPs in primary human ASMC under both non-inflammatory and inflammatory conditions. 
Compared to ASMC from healthy individuals, we observed a slight reduction in the 
constitutive gelatinolytic activity of proMMP-2 of ASMC from asthma and COPD patients. In 
addition, we showed that ASMC from healthy, asthma and COPD subjects had a similar 
kinetic profile of proMMP-2 secretion. Although the gelatinolytic activity of ASMC in lung 
diseases is not well described, other studies have reported increased MMP-1 and MMP-12 
expression and secretion in asthmatic ASMC [18, 19]. Together with our observations, these 
findings suggest that ASMC-derived MMPs are differently regulated during pathological lung 
tissue remodeling. Furthermore, it has been reported that MMPs influence ASMC behaviors 
and functions, such as proliferation and migration [13, 17]. In addition to ECM degradation, 
MMPs can proteolytically process cytokines, chemokines and growth factors, suggesting that 
ASMC-derived MMPs may contribute to cell proliferation and ECM synthesis, thus 
potentiating the remodeling process [20, 21]. 
The role of the current asthma and COPD therapy in the regulation of MMPs production by 
mesenchymal cells is poorly understood. This study is the first one to address the effect of 
corticosteroids and LABA on gelatinolytic activity from primary human ASMC from healthy, 
asthma and COPD patients and we showed that both corticosteroids and LABA, alone or in 
combination, had no effect on proMMP-2 activity under serum-free condition. Previous 
studies mainly investigated the effect of corticosteroids on inflammatory cells-derived MMPs 
in serum, sputum and BALF of asthma patients. Hoshino et al. reported that 6 months of 
treatment with corticosteroids in asthmatics significantly reduced collagen deposition in the 
basement membrane via the downregulation of MMP-9 and upregulation of TIMP-1 
expression [22]. Furthermore, the serum MMP-9:TIMP-1 ratio has been shown to correlate 
with corticosteroids response in severe asthma [5]. In regard of the effect of corticosteroids on 
MMPs in BALF from asthma patients data are controversially discussed. Mautino et al. 
reported a significant decreased levels of MMP-9 in BALF of corticosteroid-treated 
asthmatics close to levels measured in healthy subjects [3]. In contrast, no change in MMP-9 
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and TIMP-1 levels were reported in BALF and sputum of patients with mild asthma after 
budesonide treatment [23].  
Our data indicate that ASMC do not contribute to MMP-9 levels in sputum or BALF in 
asthma patients. Based on data we previously presented at the European Respiratory Society 
meeting using an organoid model, we suggest that MMP-9 may originate from the epithelial 
cells, levels of which were decreased by corticosteroids [24]. An interesting study by 
Hakonarson et al. reported that dexamethasone repressed the IL-1β/TNF-α-induced gene 
expression of MMP-3, MMP-10 and MMP-12 in rabbit ASMC [25]. Accordingly, IL-1β-
induced MMP-12 activity and expression was downregulated by dexamethasone in human 
ASMC [18]. Therefore, the effects of corticosteroids and LABA on MMPs expression, 
secretion and activity are MMP-specific and cell type-specific. In addition, the origin of 
various MMPs may depend on various factors, such as the source of samples, inflammatory 
status of the patient, severity of the disease, dose and duration of the treatment. Nevertheless, 
the role of MMP-2 and MMP-9 released by ASMC under inflammatory conditions needs 
further attention as both gelatinases were reported to be crucial for the infiltration of 
inflammatory cells and induction of airway hyperresponsiveness in a murine model of allergic 
asthma [26]. 
In conclusion, this study showed that the constitutive secretion of proMMP-2 over time was 
similar in ASMC from healthy, asthma and COPD subjects and was not affected by 
corticosteroids and/or LABA. Our findings suggest that corticosteroids have no effect on the 
constitutive gelatinolytic activity in mesenchymal cells. These findings may provide some 
explanations for the inefficacy of the current asthma and COPD therapy to reverse the 
remodeling process. Therefore, further investigations are needed to fully understand the effect 
of corticosteroids and/or LABA on ASMC-derived MMPs/TIMPs under both non-
inflammatory and inflammatory conditions. 
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4.3. EFFECT OF CORTICOSTEROIDS AND LABA ON TOTAL ECM AND COLLAGEN 
DEPOSITION BY PRIMARY HUMAN ASMC 
 
Background and Aims of the study 
ASMC play a key role in asthma specifically in the response to allergens and by controlling 
airflow. The airway wall of asthma patients is thicker compared to healthy individuals due in 
part to smooth muscle hyperplasia and hypertrophy and increased ECM deposition. In the 
area of the muscle bundles, ASMC express and release a variety of ECM molecules [1-3]. 
Various pro-inflammatory and pro-fibrotic mediators, including TGF-β1, are increased in 
asthma and COPD patients, and further stimulate ECM secretion by ASMC, thereby 
potentiating the remodeling process. In turn, ECM components may influence the phenotype 
and function of ASMC, such as cell proliferation, survival, migration, mediator synthesis and 
plasticity [4-8]. Thus, the modulation of ASMC-derived ECM components may influence the 
overall lung tissue remodeling in both asthma and COPD. 
Many clinical studies have reported that corticosteroids and LABA are ineffective in 
preventing or reversing airway remodeling in asthma and COPD patients. Although the 
complex interaction between the ECM and ASMC is being widely investigated, little is 
known about the effect of corticosteroids and LABA on ECM synthesis, deposition and 
regulation by ASMC in vitro. Therefore, the aims of this ongoing study are: (i) to assess the 
effect of corticosteroids and LABA on total ECM and collagen deposition by ASMC from 
healthy individuals under non-inflammatory and inflammatory conditions; (ii) to investigate 
whether total ECM and collagen deposition by ASMC is altered in asthma and COPD; and 
(iii) to compare the effect of corticosteroids and LABA, alone or in combination, on total 
ECM and collagen deposition by ASMC from asthma and COPD patients. Here we present 
preliminary data on ASMC from healthy subjects only.  
Experimental design 
Based on our cell culture model established in fibroblasts [9], confluent serum-deprived 
ASMC from healthy individuals under 0.3% albumin were assumed to reflect a non-
inflammatory condition. To mimic an inflammatory environment ASMC were stimulated 
with 5% FCS and/or TGF-β1 (2.5 ng/ml). In addition, ASMC were treated with 
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dexamethasone, budesonide, formoterol or salmeterol at concentrations ranging from 10-10 to 
10-6 M in 0.3% albumin or 5% FCS for 48 h. Total ECM and collagen deposition were 
determined by [3H]-proline incorporation (Annex). No statistical analysis was performed due 
to the low number of experiments. 
Results  
5% FCS and TGF-β1 synergistically increased total ECM and collagen deposition 
The [3H]-proline incorporation data are expressed in cpm. As shown in Fig. 4.6A, 5% FCS 
increased total ECM deposition compared to 0.3% albumin (5256 ± 223 versus 1679 ± 618 
cpm). TGF-β1 tended to increase total ECM deposition compared to 0.3% albumin (2225 ± 
412 versus 1679 ± 618 cpm). Stimulation with 5% FCS and TGF-β1 synergistically enhanced 
total ECM deposition compared to 0.3% albumin and to each stimulus alone (10 800 ± 
2571 cpm; Fig. 4.6A). Similar results were observed for collagen deposition. Stimulation with 
5% FCS induced a 4-fold increased collagen deposition compared to 0.3% albumin (2745 ± 
282 versus 746 ± 293 cpm; Fig. 4.6B). TGF-β1 applied in serum-free condition slightly 
increased collagen deposition (1064 ± 167 cpm). When combined, 5% FCS and TGF-β1 
synergistically increased collagen deposition by 10-fold compared to 0.3% albumin (7309 ± 
1554 cpm; Fig. 4.6B). 
Effect of corticosteroids on total ECM and collagen deposition 
We then investigated the dexamethasone and budesonide dose-response on total ECM and 
collagen deposition by ASMC. The results are expressed as percentage of change from 
control, corresponding to [3H]-proline incorporation in 0.3% albumin and 5% FCS 
standardized to 100%. Dexamethasone had no clear effect on total ECM deposition in 0.3% 
albumin but further increased the FCS-induced total ECM deposition by approximately 60% 
at concentrations ≥ 10-8 M (Fig. 4.7A). Similar results were obtained with budesonide, having 
no clear effect on total ECM deposition in 0.3% albumin but dose-dependently increasing the 
FCS-induced total ECM deposition, reaching a 30% increase at concentrations ≥ 10-8 M (Fig. 
4.7C). 
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Figure 4.6. Effect of 5% FCS and TGF-β1 on total ECM and collagen deposition by ASMC. Confluent 
serum-deprived ASMC from healthy subjects were stimulated with 0.3% albumin or 5% FCS and/or TGF-β1 for 
48 h. (A) Total ECM and (B) collagen deposition were determined by [3H]-proline incorporation. Bars represent 
means ± SEM expressed in cpm (n = 2-3 cell lines). 
 
 
Figure 4.7. Effect of corticosteroids on total ECM and collagen deposition in the presence or absence of 
serum. Confluent serum-deprived ASMC were treated for 48 h with increasing concentrations (10-10 to 10-6 M) 
of (A, B) dexamethasone and (C, D) budesonide in 0.3% albumin or 5% FCS and total ECM and collagen 
deposition, respectively, were determined by [3H]-proline incorporation. Bars represent means ± SEM expressed 
as percentage of change from control, where 0.3% albumin and 5% FCS were defined as 100% (n = 1 cell line). 
 
In regard to collagen deposition, dexamethasone had opposite effects dependently on the 
presence or absence of serum. Dexamethasone dose-dependently decreased collagen 
deposition under serum-free condition and the reduction reached 28% at 10-6 M. In 5% FCS 
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dexamethasone had the opposite effect, increasing collagen deposition in a dose-dependent 
manner (Fig. 4.7B). Budesonide in 0.3% albumin tended to slightly increase collagen 
deposition and in 5% FCS it further increased the FCS-induced collagen deposition by 20% at 
10-10 M up to 53% at concentrations ≥ 10-8 M (Fig. 4.7D). 
LABA decreased total ECM and collagen deposition 
Then we assessed the dose-response of two LABA on total ECM and collagen deposition 
under serum-free and 5% FCS conditions. Salmeterol (Fig. 4.8A,B) and formoterol 
(Fig. 4.8C,D) reduced total ECM and collagen deposition in both 0.3% albumin and 5% FCS. 
However, the decreasing effects which ranged from 18 to 40% compared to non-treated cells 
were not clearly dose-dependent. 
 
 
Figure 4.8. Effect of LABA on total ECM and collagen deposition in the presence or absence of serum. 
Confluent serum-deprived ASMC were treated for 48 h with (A, B) salmeterol and (C, D) formoterol at 
concentrations from 10-10 to 10-6 M in 0.3% albumin or 5% FCS and total ECM and collagen deposition, 
respectively, were determined by [3H]-proline incorporation. Bars represent means ± SEM expressed as 
percentage of change from control, where 0.3% albumin and 5% FCS were defined as 100% (n = 1 cell line). 
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Discussion 
These preliminary data showed that serum and TGF-β1 synergistically increased total ECM 
and collagen deposition by primary ASMC from healthy subjects. Corticosteroids had no 
clear effect on total ECM and collagen deposition under serum-free condition and further 
increased the FCS-induced total ECM and collagen deposition in a dose-dependent manner. In 
contrast, LABA decreased total ECM and collagen deposition independently of the presence 
of serum.  
ASMC hyperplasia and airway wall thickening are pathological features of airway remodeling 
in asthma and COPD. In vitro, ASMC express a wide variety of ECM macromolecules [3]. 
Here we showed that 5% FCS and TGF-β1 increased total ECM and collagen deposition by 
ASMC. In primary human lung fibroblasts, we recently reported that 5% FCS and TGF-β1 
increased total ECM and collagen deposition to a similar extent and had an additive effect 
when combined [9]. Many studies have reported that TGF-β1 stimulation upregulated 
expression of several ECM genes in ASMC [1, 10, 11]. Furthermore, it was recently shown 
that the TGF-β1-mediated induction of fibronectin and collagen type I production by ASMC 
occurred in part by the autocrine release of CTGF [12]. 
Regarding the effect of the actual therapy for asthma and COPD, we showed that 
corticosteroids and LABA had similar effect on total ECM and collagen deposition by ASMC 
as described in fibroblasts [9]. In contrast to the significant inhibition on ECM deposition by 
corticosteroids in fibroblasts, no clear effect of corticosteroids under serum-free condition was 
obtained in ASMC. Interestingly, in both fibroblasts and ASMC corticosteroids further 
increased the FCS-induced total ECM and collagen deposition. LABA had a inhibitory effect 
under non-inflammatory and inflammatory conditions in both cell types.   
Our collaborators previously showed increased ECM proteins deposition following 
sensitization of ASMC with asthmatic serum and no effect of corticosteroids [2]. In contrast, 
Hakonarson et al. showed in ASMC upregulation in the expression of ECM-related genes 
following stimulation with the pro-inflammatory cytokines IL-1β and TNF-α and that pre-
treatment with dexamethasone repressed not only the upregulated inflammatory genes but 
also ECM genes [13]. Together with these studies, our findings suggest that ASMC from 
healthy individuals may respond differently to corticosteroids and/or LABA depending on the 
inflammatory stimuli. Our experiments need to be repeated for confirmation of the described 
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results and the effect of the drug combination should also be addressed. Further investigations 
comparing total ECM and collagen deposition by ASMC from healthy, asthma and COPD 
patients are needed. In addition, the effect of corticosteroids and LABA on ECM deposition 
by ASMC from asthma and COPD subjects under non-inflammatory and inflammatory 
conditions will be addressed as well as the signaling pathways involved in the drug effects.  
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CHAPTER 5 
KEY FINDINGS, CONCLUSION AND PERSPECTIVES 
 
5.1. KEY FINDINGS 
In the present thesis, we have shown that the effect of corticosteroids and LABA regarding 
ECM deposition depends on the inflammatory environment surrounding mesenchymal cells. 
Using different experimental approaches we were able to answer our three original objectives.  
• This thesis provides the first description of an in vitro model mimicking inflammatory 
and remodeling conditions. Indeed, we have demonstrated that serum stimulation 
induced IL-6, IL-8 and TGF-β1 release as well as cell proliferation in primary human 
lung fibroblasts and that these two inflammatory responses were inhibited by 
corticosteroids. In addition, FCS and/or TGF-β1 increased total ECM, collagen and 
GAGs deposition, reflecting active tissue repair. 
• Using our model, we showed that the inhibitory effect of corticosteroids on total 
ECM, collagen and GAGs deposition was reversed in 5% FCS. In contrast, LABA 
decreased total ECM and collagen deposition independently of the presence of serum 
but had no effect on GAGs deposition. Interestingly, combined corticosteroids and 
LABA showed an additive effect by decreasing total ECM and collagen deposition 
under serum-free condition and counterbalanced each other in FCS. However, the 
combined treatment had the same effect on GAGs secretion and deposition as 
corticosteroids alone. 
In addition, we showed that the inhibitory effect of corticosteroids on total ECM and 
collagen deposition under non-inflammatory condition was partly mediated via the GR 
and collagen gene expression, whereas the corticosteroid-induced ECM deposition in 
the presence of serum was not mediated via the GR but was associated with 
upregulation of CTGF mRNA expression. The effect of LABA was partly mediated 
via the β2-adrenergic receptor and did not involve gene expression. 
• We expanded our research to ASMC originating from healthy, asthma and COPD 
patients. We showed no difference in the constitutive GAGs secretion and deposition 
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between ASMC from healthy, asthma and COPD subjects and in their response to 
FCS, corticosteroids and/or LABA. Under serum-free condition corticosteroids but not 
LABA, decreased GAGs secretion and deposition. Surprisingly, in 5% FCS 
corticosteroids decreased GAGs secretion and had no effect on GAGs deposition. 
Furthermore, we showed that corticosteroids and LABA had similar effect on total 
ECM and collagen deposition as observed in fibroblasts. Finally, we demonstrated that 
the drug effects on ECM deposition were not modulated by MMPs. 
5.2. CONCLUSION 
In conclusion, our data suggest that the effect of corticosteroids on ECM deposition by 
fibroblasts is generally altered by serum, while this is not the case for LABA. Our in vitro 
model demonstrates new effects of the corticosteroids and LABA, alone or in combination, on 
ECM deposition by mesenchymal cells. Our findings indicate that in order to block the 
progression or to reverse airway remodeling in asthma and COPD patients, the actual therapy 
should be adjusted to the inflammatory status of the patients and the concentrations well 
controlled to avoid the occurrence of important side effects. 
5.3. PERSPECTIVES 
Our data raise the question whether it would not be more beneficial to start corticosteroids 
treatment at an early stage of asthma to prevent inflammation and consequently airway 
remodeling instead of trying to reverse established lesions. Addressing theses issues would 
provide more information about the role of structural cells and the importance of 
inflammation in the onset and progression of tissue remodeling and might elucidate which 
elements of the remodeling process can be prevented. This is indeed a hypothesis that could 
be tested using our in vitro model by pre-treating cells with corticosteroids before serum 
stimulation and measurement ECM deposition.  
Furthermore, ECM deposition during airway inflammation is regulated by altered cell 
phenotype and response to various cytokines and growth factors. In this regard, signals in the 
inflamed airways of asthma and COPD patients could modulate ECM production by 
fibroblasts and ASMC and influence their response to therapy. Therefore, it would be of great 
interest to assess ECM deposition by fibroblasts from asthma and COPD patients and to 
further investigate their response to corticosteroids and LABA. An alternative would be to 
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investigate the influence of serum or BALF from asthma and COPD patients on ECM 
synthesis by healthy fibroblasts. 
Finally, DNA microarray represents another interesting approach, which might elucidate 
potential mediators and mechanisms involved in the opposite effect of corticosteroids on 
ECM deposition by lung fibroblasts under non-inflammatory and inflammatory conditions. 
Obviously, the extrapolation of such experimental findings to the clinical management of 
asthma and COPD requires caution. However, they may provide insights into the mechanisms 
modulating lung tissue remodeling and may lead to new drug targets or help to optimize 
current therapy of asthma and COPD. 
ANNEX 
MATERIALS AND METHODS 
 
Primary human lung cell cultures 
Ethical committee 
The primary human lung cell cultures were established from macroscopically normal parts of 
peripheral lung tissue obtained from patients undergoing partial lung resection as part of a 
lung cancer therapy. This protocol was approved by the Ethical committee of the Faculty of 
Medicine, University Hospital Basel (#M75/97). Tissues were collected by Dr. Franco 
Gambazzi from the Department of Thoracic Surgery. In addition, primary ASMC from 
healthy, asthma and COPD patients were provided by our collaborators from The Woolcock 
Institute of Medical Research (University of Sydney, Australia). Ethical permissions for these 
studies were obtained from the University of Sydney and the Central Sydney Area Health 
Service, and all patients gave written and informed consent. 
Primary human lung fibroblasts 
Primary human lung fibroblast cultures are well established in our laboratory and their 
phenotype was previously characterized and described by our group [1, 2]. Briefly, fibroblasts 
were established from sterile lung tissue samples stored at 4°C in sterile PBS (Cambrex Bio 
Science, Verviers, Belgium). Tissue samples were cut into small pieces of 1-2 mm3 and 16-20 
pieces were placed into 75 cm2 flasks pre-wetted with 5 ml of RPMI 1640 (2.1 mM glutamine 
and 25 mM Hepes; Cambrex) supplemented with 10% FCS (heat inactivated for 15 min at 
65°C; Gibco BRL Invitrogen, Basel, Switzerland) and 1% MEM-Essential minimum vitamins 
(Cambrex). Cultures were performed without antibiotics and were kept at 37°C in a 
humidified incubator containing 5% CO2. Epithelial-like cells started to grow after few days 
followed by spreading of spindle shape-like fibroblasts from the tissue pieces. Medium was 
changed twice a week until fibroblasts reached confluence around the tissue pieces. Then, 
cells were washed three times with PBS and trypsinized [0.125% trypsin (Biochrom AG, 
Berlin, Germany) and 0.01% EDTA in PBS] for 3 min at 37°C. For the first passage, cells 
were re-suspended in 10% FCS medium in the same flask to avoid any cell loss and medium 
was changed the following day. The next passages were performed according to a 1:3 ratio. 
Fibroblasts displayed a typical spindle-shaped morphology, stained positive for fibronectin 
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and laminin but were negative for von Willebrand factor, Factor VIII, cytokeratin, and smooth 
muscle actin. Fibroblasts between passages 3 and 6 were used for all experiments.  
Primary human ASMC 
ASMC were mainly obtained from our collaborators at the Woolcock Institute (Sydney, 
Australia) and were established as previously described by Carlin et al. [3]. Briefly, non-
asthmatic ASMC were obtained from bronchi of patients undergoing resection for either lung 
transplantation or carcinoma. Asthmatic ASMC were obtained from deep endobronchial 
biopsies performed by flexible bronchoscopy. Large bronchi of 5-15 mm internal diameter 
were dissected from the surrounding parenchyma. With the aid of a binocular microscope, the 
epithelial layer was removed, thus exposing the underlying smooth muscles. These smooth 
muscle bundles were dissected from the bronchi and placed into 25 cm2 tissue flasks 
containing DMEM medium supplemented with 10% FCS, 20 U/l penicillin, 20 µg/ml 
streptomycin, and 2.5 µg/ml amphotericin B (GIBCO BRL, Life Technologies, Sydney). 
ASMC grew to confluence within approximately 3 to 4 weeks and were passaged into 75 cm2 
flasks. Cells were sent to our laboratory and then cultured in RPMI medium supplemented 
with 5% FCS and 1% MEM-vitamins until confluence. ASMC were also obtained from the 
University of Basel as described above and were grown in antibiotic-free medium. All 
experiments were performed with cells between passages 4 and 9. As described by Johnson et 
al., ASMC appeared spindle shaped with central and prominent nucleoli, and pure 
populations were confirmed by positive staining for α-smooth muscle actin and calponin [4]. 
Cell stimulation and drug treatment 
Serum starvation 
Prior to stimulation and treatment, cells were growth-arrested by serum starvation for 24 h in 
low serum RPMI medium supplemented with 0.1% FCS or 0.3% human albumin. Medium 
was exchanged after 12 and 24 h to avoid auto-stimulation of the cells. 
Cell stimulation 
Stimulation at different time points with either 5% FCS or recombinant human TGF-β1 (0.1 to 
5 ng/ml; Sigma, Schnelldorf, Germany) was used to mimic an inflammatory environment. 
Corticosteroids and LABA 
The effect of corticosteroids and LABA on pro-inflammatory cytokine release, ECM 
deposition, MMPs activity, gene expression and cell proliferation was investigated in our cell 
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cultures. Three corticosteroids (dexamethasone [Calbiochem, Lucerne, Switzerland], 
fluticasone [GlaxoSmithKline, London, UK] and budesonide [AstraZeneca, Lund, Sweden]) 
and two LABA (salmeterol [GlaxoSmithKline] and formoterol [AstraZeneca]) were tested at 
concentrations ranging from 10-6 to 10-10 M for 24 or 48 h under both non-inflammatory and 
inflammatory conditions. Drugs were dissolved in DMSO, which final concentration 
(< 0.01% DMSO in the culture medium) had no effect on all measured parameters.  
GR and β2-adrenergic receptor antagonists 
We assessed whether the effects of corticosteroids and LABA on total ECM and collagen 
deposition were mediated via their receptor. Fibroblasts were pre-treated for 30 min with the 
GR antagonist RU486 (Sigma) or the β2-adrenergic receptor antagonist propranolol 
(Calbiochem), both at 10-6 M, before the addition of a corticosteroid or LABA (10-7 M).   
Cellular biology  
IL-6, IL-8 and TGF-β1 ELISA 
Conditioned cell culture media of confluent fibroblasts were collected after 48 h of 
stimulation and levels of IL-6, IL-8 (Orgenium, Helsinki, Finland), and total TGF-β1 (R & D 
Systems, Minneapolis, MN, USA) were determined by ELISA according to the 
manufacturer’s instructions.  
Total proteins concentration 
Total proteins concentration in conditioned media was measured using the Bradford protein 
assay (Bio-Rad Laboratories GmbH, Munich, Germany). The standard curve was established 
using bovine serum albumin (0-500 ng/ml) and the absorbance was measured at 595 nm with 
a microplate reader (SpectraMax 190, Molecular Devices Corporation, Sunnyvale, USA).  
Gelatin zymography 
Conditioned media were collected from ASMC after stimulation and/or treatment before 
assessing gelatinolytic activity by zymography according to the method previously detailed 
[6, 7]. Each sample (2 µg of proteins) were separated on a 10% polyacrylamide SDS gels 
containing 1 mg/ml porcine skin gelatin (Sigma) for 3 h at 50 mA constant current. After 
electrophoresis, gels were washed 2 x 30 min in 2.5% Triton-X to remove the SDS in order to 
allow the enzymes to recover their enzymatic activity. Gels were rinsed in water and then 
incubated in the enzyme activation buffer [50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 2 µM 
ZnCl2, and 0.02% Brij-35] for 18 h at 37°C. During this incubation, the activated MMPs in 
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the gels digested the gelatine substrate. The following day, gels were stained for 3 h with 
0.1% Coomassie Brilliant Blue (R-250, Bio-Rad) in 25% methanol and 10% acetic acid. Gels 
were then destained (25% methanol, 10% acetic acid) until the detection of transparent bands 
and dried overnight between two sheets of cellophane. Enzymatic activity was detected as 
colorless bands against a blue background and compared to pre-stained molecular weight 
marker (Bio-Rad). Quantification was performed by densitometry using the NIH Image J 
software and data expressed as arbitrary units (a.u.). 
Total ECM and collagen deposition 
Total ECM and collagen deposition were assessed by [3H]-proline incorporation as previously 
described by our group [8, 9]. This well-established assay measures the incorporation of [3H]-
labeled proline into protein. The percentage of proline specifically incorporated into collagen 
is determined after digestion with collagenase. In our studies, primary human lung fibroblasts 
and ASMC were seeded into 24-well plates, grown until confluence, serum-deprived for 24 h 
in 0.3% human albumin and stimulated and/or treated in the presence of 1 µCi/ml [3H]-
proline (Amersham, Little Chalfont, UK) and 10 µg/ml L-ascorbic acid for 36 or 48 h. After 
removing the conditioned media, cells were lysed with 25 mM NH4OH for 10 min at room 
temperature. The remaining deposited ECM was fixed in 70% ethanol (2 x 15 min) and 
washed 3 times with a buffer consisting of 50 mM Tris-HCl (pH 7.5), 1 mM CaCl2 and 1 mM 
L-proline. The resulting deposited ECM was then incubated with 300 µl of collagenase buffer 
[50 mM Tris-HCl (pH 7.5), 1 mM CaCl2 and 2.5 mM N-ethylmaleimide] with or without 
120 U/ml of highly purified bacterial collagenase (type VII, Clostridium histolyticum; Sigma) 
for 4 h at 37°C. The supernatants were then carefully removed and collected into scintillation 
vials. The residual ECM was solubilized by an overnight incubation in 0.3 M NaOH 
containing 1% SDS. The levels of [3H]-proline present in the supernatants and in the 
solubilized ECM was determined by liquid scintillation counting by a β-counter and 
expressed as counts per minute (cpm). All experiments were performed in duplicate.  
Modification of deposited total ECM and collagen was calculated as follows: 1) cpm in 
solubilized ECM without collagenase was defined as “total ECM deposition”; 2) (cpm in 
supernatant without collagenase x 100) / (cpm in supernatant without collagenase + cpm in 
solubilized ECM without collagenase) was defined as percentage of background; and 3) cpm 
in supernatant with collagenase – (% background x cpm in supernatant with collagenase) was 
defined as “collagen deposition”. 
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Total GAGs secretion and deposition 
Total GAGs secretion and deposition were determined by using [3H]-glucosamine 
incorporation (1 µCi/ml; Amersham) as previously described [2]. In order to measure total 
GAGs secretion, 500 µl of conditioned media were added to 2 ml of 95% ethanol containing 
2.5% (w/v) sodium acetate and incubated overnight at 4°C in order to allow protein 
precipitation. The following day samples were centrifuged at 3000 x g for 30 min at 4°C and 
the pellets were dissolved by 0.2 mg/ml pronase (pre-incubated for 30 min at 40°C to 
eliminate glycosidase activity, Streptomyces griseus; Calbiochem) in 500 µl of pronase buffer 
consisting of 100 mM Tris-HCl (pH 7.5) and 1 mM CaCl2.  Samples were incubated at 40°C 
for 1.5 h prior to an overnight protein precipitation at 4°C as above. Samples were centrifuged 
and the pellets were dissolved in 250 µl of 0.5 M NaOH and transferred into scintillation 
vials. [3H]-glucosamine was determined by liquid scintillation by a β-counter and expressed 
as cpm. 
Total GAGs were also measured in the cell layer together with the deposited ECM. Cells were 
washed twice with ice-cold PBS and lysed with 200 µl RIPA buffer [1% Nonidet P-40, 1% 
sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate (pH 7.2)]. Proteins 
were first precipitated overnight at 4°C (800 µl of 95% ethanol containing 2.5% sodium 
acetate), centrifuged at 16 000 x g for 15 min and then the remaining pellets were dissolved 
by 0.5 mg/ml pronase in 200 µl of pronase buffer for 1.5 h at 40°C. GAGs were precipitated 
overnight at 4°C, centrifuged, resuspended in 250 µl of 0.5 M NaOH and [3H]-glucosamine 
was determined by liquid scintillation.  
Cell proliferation 
Fibroblast proliferation was measured by [3H]-thymidine incorporation in newly synthesized 
DNA. Fibroblasts were seeded at a density of 5000 cells/well into 96-well plates, grown until 
60-70% confluence. Serum-deprived cells were stimulated with 5% FCS and treatments were 
applied in the presence of 2 µCi/ml [3H]-thymidine (Amersham). After 30 h of stimulation, 
cells were washed twice with PBS and lyzed (100 µl of 1 M NaOH/well). Cells were 
harvested onto filter plates using the Filtermate Unifilter-96 Harvester (PerkinElmer Life 
Sciences, Boston, USA). After drying the filter plates, 20 µl of scintillation liquid/well were 
added and incorporated [3H]-thymidine was determined in a β-counter (TopCount microplate 
scintillation counter; PerkinElmer Life Sciences). Data were expressed as cpm and all 
experiments were performed in sixtuplicate. 
© S. Goulet, 2006 130 
Molecular biology 
RNA extraction and reverse transcription 
Cells were plated in 100 x 20 mm dishes, grown until confluence and serum-deprived for 24 h 
prior to stimulation and/or drug treatment. After incubation, cells were washed twice with ice-
cold PBS, scrapped and cell pellets were collected by centrifugation at 900 x g for 10 min. 
Total RNA was isolated using RNeasy Mini kit (Qiagen, Basel, Switzerland) and RNA 
concentration and purity were measured by spectrophotometry (NanoDrop Technologies Inc., 
Wilmington, DE, USA). The A260/A280 ratio was used as an indicator of purity with optimal 
values ranging between 1.8 and 2.0 RNA samples were stored at -70°C until analysis. First 
strand cDNA was synthesized from 1 µg of total RNA using M-MLV Reverse Transcriptase 
according to the manufacturer’s instructions (Promega, Madison, WI, USA). 
Polymerase chain reaction 
cDNA was amplified using Taq DNA polymerase (Promega). PCR conditions consisted on 1) 
an initial denaturation at 95°C for 2 min, 2) denaturation at 95°C for 30 sec, primer annealing 
at 58-60°C for 30 sec, and extension at 72°C for 1 min for 20-40 cycles, and 3) a final 
extension at 72°C for 5 min. PCR products were analyzed by 1.5% agarose gel 
electrophoresis and visualized by ethidium bromide stain under UV light. The intensity of 
each band was analyzed by densitometry using the NIH Image J software and the relative 
mRNA expression of target gene was normalized to β-actin. All primers were purchased from 
MWG-Biotech AG (Ebersberg, Germany). 
Statistical analysis 
For statistical analysis, Student’s t-test was performed using the free statistic software 
package R and p < 0.05 was considered significant. 
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